Category Archives: Ones to Watch

QualityStocks “Ones to Watch”

These are firms to put on your watch list.

AzurRx BioPharma, Inc. (NASDAQ: AZRX) is “One to Watch”

June 14, 2017

With more than a century of combined experience spanning the gamut from pancreas/GI tract issues in hepato-gastroenterology and infectious disease to the development of novel non-systemic (localized) therapeutic biologics and proteomics (protein engineering), the AzurRx BioPharma, Inc. (NASDAQ: AZRX) core science team is the real strength behind the company’s developing portfolio of recombinant therapies. AzurRx has come quite a long way on the strength of its science-driven approach and today stands tall upon the IP foundation of its two main pipeline programs. The lead candidate of which, MS1819 lipase, is currently in ongoing, open-label Phase IIa trials in EPI (exocrine pancreatic insufficiency) associated with chronic pancreatitis (CP). Human trialing where this novel, orally delivered, non-systemic (non-absorbable, locally-acting, does not reach systemic circulation), yeast-derived recombinant enzyme has already shown solid dose responses at various levels with no apparent safety issues.

Given such positive Phase IIa in vivo study data (reported in mid-April 2017), where the efficacy of MS1819 is characterized by a 20 percent increase in the coefficient of fat absorption in all patients (or CFA, the primary efficacy endpoint), AZRX is confident that its lead candidate will continue to show a marked superiority to currently marketed, porcine-derived pancreatic enzyme replacement therapies (PERTs). With an anticipated completion of the MS1819 Phase IIa in the third-quarter of 2017 and strong applications for the drug in EPI associated with CF (cystic fibrosis), as well as demonstrably apparent efficacy in CP-associated EPI, the $8.50 valuation set by Zacks Small-Cap Research earlier this year (January, April) looks well within striking distance (given that the projection is based on a 2020 launch of MS1819).

A recent report from April of 2017 by GlobalData paints a bullish picture for the broader CF market with a CAGR of around 13.6 percent through 2025 when it will reach upwards of $7.6 billion on the strength of new drugs becoming available. This is exciting news when contrasted with the Transparency Market Research projection from last year, which depicts the EPI space alone to be worth around $2.85 billion by 2023, on a CAGR of some 8.3 percent, with the U.S. representing roughly 57 percent of that global pie. The PERT market is currently dominated by a small handful of players, with the AbbVie (NYSE: ABBV) drug Creon accounting for the lion’s share, and newer, more technologically advanced entrants such as Allergan’s (NYSE: AGN) Ultresa currently being seen by analysts as having the highest future growth rate.

However, these drugs and other PERTs such as Nutrizym, Pancrease and Pancrex are derived from pig pancreas gland extracts, carry a pork viral contamination risk, and thus represent a biopharma niche that is ripe for disruption by an innovator like AZRX.

PERT Demand May be Larger than Expected

Somewhere from 10 to 12 million people in the U.S. are estimated to carry the defective CF gene that leads to CF, and while the patient population is only around 30,000 or more, it can be inferred from CDC statistics that there are approximately 400 or more new cases in the U.S. alone each year (around 1,000 worldwide). CF is also no longer considered a childhood disease like it was only a few decades ago, because patients are now able to more effectively manage the disease via therapy and have an average life expectancy of around 37 years. EPI is observed to occur in 85 to 90 percent of CF patients according to research done by one of the most trusted names in pathology, Robbins Basic Pathology.

With the rate of CP around 50/100,000, and a growing awareness of the influence of diabetes on pancreatic exocrine function, the emergence of a yeast-derived recombinant enzyme therapy such as MS1819 is really something to take note of, especially due to the fact that AZRX’s offering has shown high potency in low pH environments (stable in protease and bile salt environments), and activity in long chain fats. EPI affects as many as half of all the people with insulin-dependent diabetes by some estimates, and it is well-known that CP patients typically develop type 3c diabetes. The key takeaway in all of this is that there is a growing market for MS1819, a drug which is now clearly underscoring the success of earlier Phase Ib in vitro work, during in its ongoing Phase IIa in vivo trial.

Phase IIb Enabling Trial & Successful Placement Very Bullish

CEO of AzurRx BioPharma, Thijs Spoor, was clearly pleased by extant Phase IIa results with MS1819, pointing to the observably robust dose-response pattern and overall safety characteristics. Anticipation is high that MS1819 will prove to be a more effective and safer alternative to existing PERTs. Given the warm reception by patients, as well as physicians noted by the Clinical Investigator, this drug could gobble up market share very quickly.

It’s little wonder then that the recent private placement financing (closing announced June 8) went so well, with the issuance designed to fund the MS1819 program being over-subscribed, allowing AZRX to rake in gross proceeds of some $5 million. The $3.50 priced units in the placement consisted of a share of common stock, one Series A Warrant for 0.25 shares at $4.00 (exercisable through Dec 31, 2017), and one Series A-1 Warrant for 0.75 shares at $5.50 (exercisable six months after closing through June 6, 2022).

Potential Sleeper Hit in the Wings

The second program under development by AZRX at this time is another oral non-systemic, AZX1101 (recombinant beta-lactamase derived from a bacterial source), which is in the preclinical stage for localized shielding of the GI tract against HAIs (hospital-acquired infections) associated with broad-spectrum beta-lactam antibiotic use. Beta-lactam antibiotics (especially penicillins and cephalosporins) have really come into their own as the drugs of choice for many infections, but their use is also frighteningly threatened by the emergence of increasingly resistant strains of bacteria.

This could be a nice one-two punch lineup for AZRX, with MS1819 commercialization supercharging the development ramp for AZX1101, amid a global infection control market that is on-track to run a 6.5 percent CAGR through 2021, reaching around $17.78 billion on the dominance of factors such as the growing prevalence of HAIs. It is worth noting that the Zacks Small-Cap Research doesn’t even factor the potential upside from AZX1101 into its $8.50 price target, despite the admittedly substantial market opportunity.

To take a closer look, visit

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
480.374.1336 Office

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished:

FORM Holdings Corp. (NASDAQ: FH) is “One to Watch”

May 10, 2017

FORM Holdings (NASDAQ: FH) employs a relatively simple yet extremely robust targeting matrix when it comes to acquiring new development candidates. It’s really all about what this diverse holding company can bring to table, as well as how much an otherwise promising, vetted target can benefit – whether it is additional capital and restructuring we are talking about, or full-scale rebranding and implementation of new best practice procedures. Similarly, candidates are selected that can clearly benefit from the kind of new talent recruitment, as well as tailored marketing, public relations, and visibility enhancement, that only an outfit of FORM Holdings’ caliber can provide.

The operational profile of FORM Holdings spans several wholly-owned operating units in technology, including built-to-order, rugged, field-ready mobile and computing products company, Group Mobile; the designer, developer and manufacturer of mobile device-agnostic, wire-free rapid charging and power systems, FLI Charge; and an IP monetization company, Vringo, which works a growing portfolio with more than 75 technology patents, covering everything from telecom infrastructure, remote monitoring and internet search, to ad-insertion, wireless charging, and mobile technologies. The Company also maintains an 8.5 percent stake in Infomedia, a privately-owned, leading UK-based CRM (customer relationship management) and monetization tech provider to mobile carriers and device manufacturers.

However, FORM Holdings has shifted a good deal of its overall corporate focus in recent quarters to its newly-acquired health and wellness subsidiary, XpresSpa. For, as CEO and Director Andrew Perlman recently pointed out in an interview with Bloomberg Market’s Pimm Fox, airport traffic in the U.S. was up 3.2 percent to 929 million passengers last year alone, according to the latest data from the Bureau of Transportation Statistics. XpresSpa represented approximately 70 percent of FORM Holdings’ 2016 revenues, whereas the aforementioned other four business units represented only the remaining 30 percent. XpresSpa raked in some $43.6 million last year, with hearty store level profitability margins of around 20 percent.

Unlike traditional brick and mortar retail that has seen increasingly dramatic erosion by e-commerce (as antiquated and vulnerable operations become displaced by digital commerce of some form or another), airport terminals provide a comparatively captive consumer audience that is willing to spend more for immediate satisfaction. This only becomes more and more the norm in a world where enhanced security procedures often mean longer wait times and increased stress. Indeed, checkpoint traffic rose 15 percent from 2011 to 2016, while the number of screeners declined roughly 5.5 percent. Even with TSA PreCheck, more travelers and fewer screeners has led to long wait lines and grumpy passengers.

According to the Department of Transportation, consumer complaints from all categories against airlines were up 47 percent from 2014 to 2015, and they rose another 10 percent last year. With a variety of well-publicized stories in the news recently about airline carriers failing to live up to customers’ service expectations, the welcoming promise of a pre- or post-flight XpresSpa decompression session may be just the ticket when it comes to encouraging travelers to keep flying the not-always-so-friendly skies. One look at the full-service spa offerings available – from massage, manicure/pedicure, facials, and waxing, to hair and grooming, as well as shower facilities at some locations – and even the lay investor can see why the XpresSpa business model has caught fire with travelers. This is especially true when one considers the demographic of U.S. air travelers, who have as much as double the median household income, or that of the frequent fliers, who generally have more than double the median household income and make most of their airport retail purchases on impulse due to the same factors which plague all airline travelers, such as boredom, stress, and the hectic nature of most airports.

XpresSpa is more than just a well-recognized and trusted brand that consumers have come to rely on to de-stress before or after a wearying journey. It is also the dominant player in the industry domestically with 3.3 times as many locations in the U.S. market as its next closest competitor, Be Relax, and more locations than all of its competitors combined if we look at total global market saturation (U.S. included). This is an interesting metric indeed, given that the company’s international footprint currently consists of just three stores in Amsterdam and one in Dubai. If we look at the choice CAPEX to profitability data on the Company’s new kiosks, which pulled on average about half the $1 million in sales last year that the in-line stores did, the expansion potential for this sector front-runner becomes even more tantalizing.

While XpresSpa is likely the most recognized and popular airport spa brand among travelers today, with 53 locations in 40 terminals at 22 airports, one of the real keys to building the company’s presence has been to deploy multiple locations at a single airport. For instance, the Company has seven stores and a kiosk at New York’s JFK alone, which was actually the number one large U.S. hub last year for international enplanements, and was the fifth busiest U.S. air travel hub (by total boarding).

Just to underscore the viability of this multiple location per venue model, and to dissuade investors from the notion that eight is enough when it comes to venue saturation, the company has another location slated to open at JFK in Q2 FY17. It says a lot about the business model’s expansion potential to see XpresSpa going for a ninth location at JFK (3.4 percent increase last year to nearly 28.9 million passengers), and the Company has three more locations slated for this year as well, which will make seven total new locations opened in all since the acquisition of XpresSpa was announced by FORM Holdings back in August of 2016.

Another key to the success and overall profitability of the XpresSpa model has been a superb and growing selection of retail items ranging from high-quality but affordable grab-and-go travel accoutrements, like best seller $18.00 travel pillows and $10.00 satin eye masks, to the $180.00 luxurious cashmere travel set, which includes a 100 percent silk eye mask, in addition to the 100 percent cashmere blanket, pillow, and mask cover case. Beyond travel blankets, masks and pillows, XpresSpa sells a wide variety of other spa products, including bath & body, hair and personal care items, hydrogel eye and face masks to revitalize tissues, and therapeutic massagers. The global airport retail market is on pace to hit $90 billion by 2023 according to a new report from Credence Research, and the U.S. space alone was estimated at around $4.5 billion back in 2015 by Micro Market Monitor.

Add to XpresSpa’s established store/product driven brand presence with the May 8 announcement of an exclusive partnership with hot, on-trend private label and branded product designer/manufacturer Capelli New York, and you have the formula for retail dynamite. Capelli has serious traction in the coveted junior and contemporary markets, with coordinated product lines in the fashion accessory and jewelry segments, as well as in hosiery, footwear, sleepwear, and home fashion (among others). The move to have Capelli co-produce and sell XpresSpa’s branded travel, spa products and accessories is something which should translate handily into expanded reach, brand presence, and overall gross margins. On this subject, it is worth pointing out to investors that XpresSpa is helmed by the former VP of premium, luxury and sports eyewear brand Luxottica, Ed Jankowski, who was also formerly Senior VP for gourmet Belgian chocolatier Godiva. This is a company that understands how to connect with high earners through premium offerings.

Furthermore, FORM Holdings has some big overhauls coming this year for XpresSpa, including XpresSpa 2.0 locations with improved aesthetics, layout, efficiency optimizations, and service offerings. Additionally, a new POS system (slated for Q4) will be fully integrated with the reservation system, open up expanded digital marketing capabilities, and leverage an already-signed user base of over 140,000 affinity members.

The other 30 percent of 2016 revenues is nothing to sneeze at either. Group Mobile has a solid pipeline of request for proposals with law enforcement, and an emphasis on long term corporate/municipality contracts for its rugged computing options, which are well-served by an experienced sales team who knows the prevailing hardware landscape like the back of its hand. Group Mobile saw 25 percent year over year sales growth last year to $6.6 million, even as bookings and customer commitments increased 128 percent to $12.1 million. Group Mobile serves a wide range of clients, from military and first responders to large select customers such as Macy’s. Rugged laptops, tablets and handhelds, as well as its wide range of other solutions, from body cameras to drones, are just a taste of the thousands of products from top brands that allow Group Mobile to tap an increasingly large slice of the $5 billion and growing domestic rugged mobile computing market.

FLI Charge also deserves a closer look, as it has some of the most advanced/efficient wire-free conductive technology available today. The sheer adaptability of this technology when it comes to working with essentially any battery-powered/DC device on the market today is enough to make FLI Charge worth further investigation on its own – but the usage characteristics of this technology are the real head-turners. Able to deliver wattage via a protocol that is as safe as plugging into a wall outlet, FLI Charge enablements can be embedded easily into any battery operated or DC-powered device, allowing them to be charged or powered via a pad such as the FLIway 40. This same ease of use becomes available for iPhone and Samsung Galaxy phones with FLI Charge’s FLIcases (70 percent thinner than extra battery packs), which remove the need for an enablement and allow the phone to be FLI Charged by simply setting it on the pad in any direction.

Investors can get a good look at FORM Holdings at the upcoming Oppenheimer Emerging Growth Conference, which will be held at the luxurious InterContinental Barclay Hotel in New York City next week. CEO Perlman will be available for one-on-one meetings throughout the day for those who arrange a meeting with Oppenheimer & Co. Inc.

To take a closer look, visit

Kootenay Zinc Corp. (CSE:ZNK) (OTCQB:KTNNF) is “One to Watch”

May 5, 2017

Kootenay Zinc Corp. is a mineral exploration and development company focused on discovering large-scale sedimentary-exhalative (“SEDEX”) zinc deposits. Based in Vancouver, British Columbia, the company is ideally positioned near its primary target, the Sully Property, located 18 miles east of the world-class Sullivan Mine.

Of the 22 raw materials tracked by the Bloomberg Commodity Index, zinc was the best-performing base metal in 2016. Based on a widening global supply deficit, outlook for the commodity remains strong. As the most closely tied base metal to the Chinese economy, zinc demand and prices are expected to rise well into the year 2020, putting increased pressure on zinc supply.

For 2017, Goldman Sachs has predicted a 360,000 ton shortage of zinc, along with a subsequent rise in zinc prices to $2,500 per metric ton in the first half of the year. Zinc continues to make history in the metals exchange, driving significant interest in the market amid supply constraints in concentrates and refined metal drive prices.

Ready to claim its share of the market, Kootenay Zinc is focused on its Sully Property. It comprises 1,375 hectares and overlies rocks of similar age and origin as those which host the legendary Sullivan deposit. The Sullivan mine was discovered in 1892, and is known to be one of the world’s largest SEDEX deposits. Over its 100-year lifetime, Sullivan produced approximately 150 million tonnes of ore, including approximately 300 million ounces of silver, 8 million tonnes of zinc and 8 million tonnes of lead.

Notably, geophysical data suggests that Kootenay Zinc’s Sully project and Sullivan share many geological features:

– Strata at Sully are in the same sedimentary basin as the Sullivan mine
– The exact stratigraphic time horizon at which Sullivan formed is present at Sully
– Filtered AeroMag anomalies coincident with Sullivan Time at Sully appear similar to Sullivan
– Gravity anomaly at Sully indicates excess mass of comparable magnitude to Sullivan
– Pb-Zn is present as traces in outcrop, drill core and in a soil geochemical anomaly

The squeeze in zinc supplies particularly affects China, which is both the world’s largest zinc consumer and its largest producer, with 4.9 million tons of output in 2015. Chinese manufacturers are now being forced to import zinc for use in cars, household appliances, paints, rubber products and smartphones.

Zinc’s rally shows no sign of slowing down in the near future, and companies that currently occupy stake in a zinc deposit find themselves in an enviable position over miners rushing to find new reserves. With its Sully Project, Kootenay Zinc could be on track to capture its share of the market, guided by a management team of mining directors and executives that currently lead some of the world’s best mining companies and have been involved in world-class discoveries which sold for billions of dollars. The company’s technical team includes industry experts that have worked on mega-mining projects, including the Sullivan and Voisey Bay projects.

Let us hear your thoughts: Kootenay Zinc Corp. Message Board

The Female Health Company / Veru Healthcare (NASDAQ: FHCO) is “One to Watch”

March 6, 2017

The Female Health Company / Veru Healthcare (NASDAQ:FHCO) has established for itself an extremely robust footing in the global public health sector via its hormone-free, latex-free FC2 Female Condom, the only FDA-approved female condom in a market forecast to deliver nine percent plus CAGR over the next five years. The Americas, EMEA and APAC regions alone amount to roughly half a billion plus in revenues already, according to Technavio, and while the Americas’ female condom market accounts for nearly half of the global sum, China and India will most likely drive APAC to out-pace all other regions in terms of growth by a margin of a full one percent or more.

Having originally been founded back in the ’80s during the height of the AIDS epidemic, The Female Health Company’s clear vision of bringing a best-of-breed dual protection product for women to the public health table has now fully blossomed into one of the true frontline weapons in an ongoing struggle against both unwanted pregnancy and the spread of STD/STI (sexually-transmitted disease/infection). An ingenious example of design, the FC2 utilizes a non-latex nitrile sheath that is not only safe to use with oil or water-based lubricants, it also offers increased pleasure potential for both parties, as the material warms from body heat, and possesses a very natural feel. The FC2 also offers a higher rate of protection against unwanted pregnancy and sexually transmitted infection compared to male condoms, meaning that dual-use scenarios where both solutions are deployed often result in a strong additive relationship, leading to a higher overall rate of protected sex among populations.

Empowering women in 144 countries around the world with its FC2 product, FHCO’s combined two decades plus of extensive field experience doing education and distribution programs across the globe has earned the company impeccable credentials within the industry. Whether we are talking about big multilateral entities such as USAID and UNFPA, various national ministries of health, or the key NGOs whose confidence is often the deciding factor between massive contracts or relegation to obscurity. The Female Health Company offers free sexual and reproductive health training materials, as well as FC2 usage training materials, to providers and healthcare professionals via its website (from the same curricula used in FHCO’s worldwide education programs).

Q1 unit sales of the FC2 this year were on par with 2016’s first quarter at around 6.3 million, when you pull out the 9.1 million units attributable to the extraordinarily large Brazil Ministry of Health contract shipments that FHCO fulfilled last year. If you pull out related non-recurring acquisition-related costs and outlays for securing of vital IP, both the Q1 FY17 and FY16 financial data sets look quite good. The company also raked in a $2.8 million payment in early January from its exclusive Brazilian distributor Semina, and it has been informed that more payments on the $13.1 million outstanding ($7.8 million in 2016 invoices alone) are forthcoming for FY17. Quarter-to-quarter fluctuations are par for the course here and are related to timing and shipping of sizable orders, but the underlying fundamentals are solid, as is product throughput to end markets.

The overall success of the FC2 really primed FHCO for its transformational merger with Aspen Park Pharmaceuticals, Inc. (APP) late last year in October, which added a multi-faceted forward window to the company’s revenue profile in the form of APP’s attractive portfolio of men’s health-focused pharmaceuticals and consumer health indications. FHCO will be doing business as Veru Healthcare subsequent to the merger when it comes to pharmaceuticals for men’s and women’s health and oncology, as well as for consumer health and medical devices (as opposed to the division using the corporate name brand, The Female Health Company, which will oversee FC2 when it comes to the public health market). This distinct division, Veru Healthcare, will also deploy the company’s proprietary female condom as the FC2 Female Condom in the consumer health market and Female Disposable Contraceptive Device (FC2) in the U.S. prescription market.

President and CEO of FHCO, Mitchell Steiner, MD, certainly projected confidence about the company’s revenue growth-initiating merger last month, when FHCO released its Q1 FY17 financials, and noted of FC2 that it was “without equal” when it comes to contraceptive products for women who want to defend against both pregnancy and STDs. With HIV/AIDS still the top killer of women aged 15 to 44 globally, and around 80 percent of cases occurring via heterosexual transmission, the sheer utility of a product like the FC2, which can be inserted anywhere from hours or just minutes in advance of sexual intercourse, is unquestionable, particularly in at-risk populations like sex workers, where the existence of a female-use driven, dual-protectant product like the FC2 can potentially work wonders. Research has even shown substantial indirect healthcare cost benefits to the implementation of female condom programs, with two to three times return multiples on every dollar invested in countries such as Cameroon and Nigeria.

Solid financials and a healthy logistical footprint, as essentially a preferred provider in the public health/female condom market, amply supports FHCO’s expansion/growth strategy, and it is noteworthy how shrewd a move this is from a PR standpoint for a company already so well established in women’s health. Branching out boldly into pharmaceuticals with a focus on men’s health through Veru Healthcare is marketing gold, and with such IP-reinforced, exciting sexual health products for men as PREBOOST® in the pipeline (an OTC-available, convenient, discreet, medicated individual wipe designed to curb premature ejaculation), serious multi-pronged revenue growth may be on the near horizon for FHCO.

A disposable, pre-moistened wipe that employs a highly effective yet safe topical anesthetic, PREBOOST was designed by Clinical Professor of Urology and Reproductive Medicine at New York Presbyterian Hospital/Weill Medical College of Cornell University Dr. Fisch to solve application problems associated with industry-standard creams and sprays, while simultaneously providing powerful, yet subtle, skin desensitization. Available in easy to carry single-use packets, roughly the size of an individually-wrapped condom, PREBOOST is easy to apply without mess, and it doesn’t interfere with the pleasure from an orgasm.

The company has already sought Orphan Drug status from the FDA for its MSS-722, a patented and proprietary treatment for male infertility that would be the first orally-available option for such indications to come to market (only currently FDA-approved standard is HCG/FSH injections). The company is in a very good position here as the Trump administration moves to speed up the new drug approval process, and MSS-722 can effectively piggyback on extant clinical and nonclinical data for CLOMID (clomiphene citrate) tablets, which are currently being used as first line therapy in 90 percent of idiopathic (having an unknown pathogenesis, or spontaneous origin) infertile men. With a nice guidance follow up late last year in December to the company’s earlier pre-IND meetings with the FDA, FHCO is now gearing up for Phase 2 clinical trials of MSS-722 and expects an NDA filing sometime in 2019.

Another near-term viability (NDA expected this year) indication picked up under the merger is Tamsulosin DRS, a delayed-release sachet, novel oral powder-like formulation targeting Benign Prostatic Hyperplasia (BPH), which is set to hit $4.9 billion by 2024, according to research and consulting firm GlobalData, over which time the space will cook along at an impressive 8.23 percent CAGR. Tamsulosin DRS contains the same API (active pharmaceutical ingredient) as Tamsulosin hydrochloride, developed by Astellas (OTC: ALPMY; ALPMF) and typically marketed in the U.S. under the trade name FLOMAX®, for BPH, or enlarged prostate. A new formulation here by FHCO would knock directly on the front door of the roughly $3.5 billion domestic generic/FLOMAX market, as well as address the broader $4.5 billion (QuintilesIMS) U.S. BPH alpha blocker space. The development strategy here should seem familiar to readers, as FHCO can once again utilize extant safety and efficacy data (in this case FLOMAX data), in order to significantly benefit shareholders.

Also in the pipeline from FHCO’s Veru Healthcare division are APP-944 for hot flashes in men undergoing prostate cancer hormone therapy, which would be the first approved oral drug in this area (NDA expected in 2020), and two more oral drugs slated to NDA in 2022, APP-111/APP-112. The first of these, APP-111, is a third line hormonal therapy for advanced prostate cancer with phase 1 studies planned to take place in 2018. This will lead directly to an IND filing and APP-112 studies in gout (the most common form of inflammatory arthritis in men) the following year.

FHCO is making all the right moves to wrangle a revenue growth herd through the Veru Healthcare portfolio, and this growth strategy seems to have been marvelously handcrafted by management. Moreover, the company has recently executed a series of key appointments in support of its growth strategy, from the most recent tapping of 20-year veteran analytical chemist Matthew C. Gosnell, Ph.D. for the Senior V.P. of Manufacturing role, to the appointment in January of sales and marketing heavyweight Brian J. Groch (who has over three decades in pharma and biotech) as the company’s new CCO.

To learn more, visit or

Revance Therapeutics, Inc. (RVNC) is “One to Watch”

December 8, 2016

Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company focused on the development, commercialization, and manufacture of botulinum toxin products for use in aesthetic and therapeutic indications, including dermatology and neurology, recently announced its operating results for the third quarter of 2016 ended September 30.

A summary of the company’s financial results highlighted research and development expenses of $10.3 million for the three-month period, $2.7 million less than in the same quarter of 2015. The decrease in expenses was largely attributable to a reduction in clinical trial activities. Research and development costs for the nine-month period were up $5.3 million.

The increase in overall expenses for the company came from an increase in personnel costs and manufacturing activities. In addition, the company recently acquired the necessary patents for botulinum toxin and put forward patent applications for Botulinum Toxin Research Associates, Inc. (BTRX).

On November 29, Aegis Capital Corp. ( initiated coverage on Revance Therapeutics, Inc., giving the company a ‘Buy’ rating with a price target of $28 per share. Aegis gave the ‘Buy’ rating based on the company’s opportunity to tap into the $3 billion botulinum toxin market, which is expected to reach $5.6 billion by 2020.

With Botox currently holding approximately 85% of the market share, Aegis reported that RT002, RVNC’s drug candidate for the treatment of moderate to severe glabellar lines in adults, will likely stand out from competitors in the market. This has been put down to the fact that, unlike other drugs, RT002 targets specific areas, effectively limiting its spread to other regions.

Aegis expects RT002 to gain a market share of approximately 21% by 2025, as long as phase III trials prove to be as positive as the company’s phase II BELMONT study. RT002 is also currently being evaluated as a potential treatment for plantar fasciitis, a condition for which corticosteroids are the first method of treatment. As a result, the drug could also be the first of its kind to gain FDA approval for this indication.

Other analysts have also taken an interest in Revance. According to Cerbat Gem Market News and Analysis (, “two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock.”

Reiterating the optimism regarding Revance’s forward growth potential, a number of large investors have recently increased their stakes in the company. BlackRock Group Ltd., BlackRock Advisors LLC, FineMark National Bank & Trust, and American International Group, Inc. all raised their positions in Revance during the second and third quarters of this year by 4.3%, 15.8%, 750% and 10.9%, respectively. At close of market yesterday, the stock was selling at $16.80 per share.

For more information, visit the company’s website at

The Trade Desk, Inc. (TTD) is “One to Watch”

The Trade Desk, Inc. (NASDAQ: TTD) is a technology company that allows buyers to use proprietary data to better target their advertising dollars. With The Trade Desk platform, organizations are able to use fully automated and programmatic means to buy advertising space on a range of media where specific consumers are more likely to use their products or services. Organizations are able to create, manage, and optimize digital advertising campaigns in formats such as display, video, audio, and more.

Headquartered in Ventura, California, with other offices in the U.S, Europe, and Asia, TTD offers an integrated feature set to its customers that includes omnichannel targeting, data management that gives insight into audiences, enterprise APIS, and HD reporting. The company runs through a self-service, cloud-based platform, offering services across a multitude of devices, including mobile devices, computers, and television.

Most recently, The Trade Desk, Inc. was ranked number 55 on the Deloitte’s 2016 Technology Fast 500™ ( list of the fastest growing media, telecommunications, technology, energy, and life science companies in North America. The ranking for both private and public companies is based on the percentage of fiscal year growth between 2012 and 2015. TTD grew by over 1,800% during that period.

Earlier in November, The Trade Desk reported its financial results for the third quarter of 2016 ( Since becoming a public company in September, the company reported an increase of over 80% in revenue. Revenue for the third quarter came in at $53 million, compared to $28.8 million during the third quarter of 2015.

Highlights of the report included the fact that TTD’s customer retention rate was over 95% for the quarter, and the company is expanding with new offices expected in Orange County, California, and Hong Kong, alongside plans to open new offices in both Europe and Asia Pacific. The company is aiming to report revenues of up to $62 million for the fourth quarter of 2016 and an adjusted EBITDA margin of 30%.

According to Cerbat Gem Market News and Analysis (, The Trade Desk’s report of $0.24 earnings per share for the quarter was higher than Thomson Reuters’ consensus estimate by $0.03. Equities research analysts have made predictions of $0.85 EPS for the company for the current fiscal year.

Jefferies Group and Cantor Fitzgerald gave The Trade Desk a ‘Buy’ rating with target prices on the stock of $35 and $30, respectively. The company received a consensus ‘Buy’ rating with an average price target of $33.13.

For more information, visit the company’s website at

Daktronics, Inc. (DAKT) is “One to Watch”

Daktronics, Inc. (NASDAQ: DAKT), a company that designs, manufactures, and sells electronic display systems and related products on a global scale, has been the topic of several reports since the company announced breaking into a new 52-week high on November 25, 2016. ( announced shares for the company reached a peak of $10.78, closing at $10.64 after opening at $10.46, a move of over 2% is just one day.

As a result, Zacks Investment Research upgraded the company from a ‘Hold’ rating to a ‘Strong Buy’, with a target price of $12 per share. Needham & Company LLC reaffirmed a ‘Buy’ rating, with a target price of $11, up from $9.50 previously. Lastly, The Street raised the company’s rating from a ‘Hold’ rating to a ‘Buy’ rating.

Daktronics, Inc. released its second quarter fiscal 2017 results on November 22, 2016, reporting earnings of $170 million, over $8 million more than estimates set by analysts. The revenue for this quarter was up 7.8% compared to the same quarter last year, and DAKT reported a return on equity of just under 5% with a net margin of 1.64%, all according to The Cerbat Gem Market News and Analysis (

In addition, various hedge funds have increased their stakes in the company. BlackRock Fund Advisors and BlackRock Institutional Trust Company N.A. have both increased their stakes in Daktronics, by 11% and 0.9%, respectively, giving them ownership of more than two million and 900,000 shares each. Vanguard Group, Inc. and Dimensional Fund Advisors LP also increased their stakes, giving them ownership of more than 1.8 million shares each. Lastly, State Street Corp. increased its stake in DAKT, giving it stock worth over $4.5 million. As a result, institutional investors and hedge funds now own over 46% of Daktronics stock.

On December 2, 2016, Daktronics announced that its board of directors approved a regular quarterly cash dividend of $0.07 per share, payable on December 23. This announcement was made very shortly after the company was awarded a multi-million dollar project by the state of Nevada, project NEON, which involves widening Interstate 15, the busiest road in Nevada.

For more information, visit the company’s website at

Momenta Pharmaceuticals, Inc. (MNTA) is “One to Watch”

December 2, 2016

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) is a biotechnology company focused on the development of generic versions of complex drugs. The company is in the business of discovering and developing new therapies for oncology and autoimmune indications. Currently, the company has four products still in the development stage (hsIVIg, M230, five biosimilar programs, and M834), two in clinical stage one trials (M281 and M923), one in the process of being BLA and NDA accepted (40 mg/ml COPAXONE®), and two already being sold at market (LOVENOX® and 20 mg/ml COPAXONE®).

Most recently, the company announced positive top-line phase III results for M923, a biosimilar HUMIRA® which is used in patients with moderate to severe chronic plaque psoriasis. Out of all the subjects who took part in the study, 75% showed a reduction in the psoriasis area and the severity index (PASI-75) was equal between both M923 and HUMIRA® after the 16-week treatment. Although the drug has been developed and commercialized by both MNTA and Baxter Bioscience, now part of Shire, MNTA is expected to take over M923 in order for Shire to continue its focus on treating patients with rare diseases.

Aegis Capital Corp. (, initiated coverage on the company on November 22, 2016, giving MNTA a ‘Hold’ rating with a price target of $15 based on the fact that the commercial launch of 40 mg Glatopa (a generic equivalent of COPAXONE®) is not expected for 2017 and that phase III trial results had not yet been disclosed. With these now showing promising results, it is worth noting that Aegis Capital Corp. stated, “If positive the M923 timeline has the potential to include a submission for marketing approval around mid-2017”.

According to Baseball News Source (, Momenta Pharmaceuticals, Inc. has been on the radar for many analysts, receiving a consensus rating of ‘Buy’ from the 10 analysts covering the stock. The average price target from brokers for the next year is $16, with one research analyst giving the company a ‘Sell’ rating, three giving it a ‘Hold’ rating, and six offering a ‘Buy’ recommendation. Analysts included Stifel Nicolaus, Maxim Group, Zacks Investment Research, Cowen and Company, and Aegis Capital Corp., among others.

In addition to the above, a number of investors have recently changed their stakes in the company’s stock. Pacad Investment Ltd., Jane Street Group LLC, Dynamic Technology Lab Private Ltd., Profund Advisors LLC, and Cornerstone Capital Management Holdings LLC acquired new stakes in Momenta Pharmaceuticals, Inc., all of which were worth more than $100,000 individually. Hedge funds and investors now own approximately 85% of MNTA’s stock.

Momenta reported its financial results for the nine months ended September 30, 2016 early last month. For the nine-month period, the company reported total revenue of just over $75 million, which included just under $59 million in revenues from Sadoz’s sale of Glatopa®. Recently, the company traded up by more than 0.70%, reaching $14.15 per share. As of the end of September, Momenta had cash and cash equivalents of $309 million. The company has a market cap of $975.74 million with revenue up 2067.7%, as compared to the same time last year.

For more information, visit the company’s website at

Citius Pharmaceuticals, Inc. (CTXR) is “One to Watch”

December 1, 2016

Citius Pharmaceuticals, Inc. (OTCQB: CTXR), a specialty biopharmaceutical company that develops and commercializes therapeutics products, has been a topic of conversation among analysts since the initiation of its phase III clinical trial of Mino-Lok™, an antibiotic lock solution used to salvage infected central venous catheters and treat bloodstream infections that stem from catheters.

This phase III randomized, double-blind, multi-center study involves 700 patients and has a primary goal of measuring whether or not the majority of subjects have overall success maintaining the treated central venous catheters during the cure test in week eight. The company will also be testing the drug for safety, tolerability, vital signs, serious adverse events, physical examinations, and clinical laboratory evaluations.

According to the company, the phase III clinical trial is expected to take two years to complete, with enrollment of the first patient anticipated for the beginning of 2017. Citius also has a second drug in late stage development, a hydrocortisone and lidocaine cream, which the company expects to become the first prescription product to treat people with hemorrhoids in the U.S. market that is approved by the Food and Drug Administration (FDA).

The company has been described by Insider Financial ( as one of the most exciting situations it has seen in small caps, and, in October of this year, Oracle Dispatch ( said, “Citius Pharmaceuticals, Inc. is a micro-cap stock that’s grabbed hold of the attention of traders during the stock’s recent bounce off of key support in the $0.60-$0.75 ranged.” The company is currently trading at $0.46 per share, representing a 4.55% growth rate.

According to the article by Insider Financial, Citius Pharmaceuticals recently completed a private placement offering of 7.6 million units for net proceeds of over $4 million. Citius Pharmaceuticals, Inc. now has a market cap of approximately $54.7 million, with total assets equating to over $23 million. The combination of two promising drugs on the horizon and an investment of $3 million in the company from Chairman Leonard Mazur (in exchange for five million restricted shares) gives CTXR sufficient funding to move forward.

For more information, visit the company’s website at

Matinas BioPharma Holdings, Inc. (MTNB) is “One to Watch”

Matinas BioPharma Holdings, Inc. (OTCQB: MTNB), is a biopharmaceutical company still in its clinical stages, focused on identifying and developing treatments for fungal and bacterial infections. Founded in 2012, the company’s goal is to change the way in which potent medicines are delivered and administered, with the aim of giving both physicians and patients better, safer, and more effective solutions to fight these infections.

MTNB is working toward unique benefits through its lead drug candidates, MAT2501 and MAT2203. These benefits include oral administration and bioavailability, multi-organ protection, and targeted delivery directly to the infected areas. MAT2501 is used to treat gram negative bacterial infections, and MAT2203 is a drug used in patients with refractory mucocutaneous candidiasis.

Most recently, the company announced that it has started enrollment and that the first group of patients have been dosed in its phase II clinical study of MAT2203. The phase II study is a randomized, multicenter, evaluator blinded study for which approximately 75 patients will be enrolled. In addition, the company is in the process of evaluating the drug in a phase IIa open label dose titration study. The study is being undertaken to establish whether or not the drug is efficient, safe, and tolerable for patients with a long standing or recurrent mucocutaneous candidiasis infection.

As a result of this progression, Aegis Capital Corp. ( recently updated the company to a ‘Buy’ rating with a target price of $8 per share based on its estimated FY2022 EPS of $2.55 per share. This news came after the company reported that its coming milestones for the phase II study of MAT2203 and phase I study of MAT2501 are on schedule. However, Aegis is not the only one to review Matinas BioPharma Holdings, Inc.

Earlier this month, Maxim Group ( initiated coverage on Matinas BioPharma Holdings, Inc., offering the company a ‘Buy’ rating. In addition to these reports, ( stated that if the company succeeds in its phase II trial, it could take over Gilead’s $350 million market for its own version of the drug. According to a report from The Cerbat Gem Market News and Analysis (, MTNB has been trading at approximately $1.54 per share with a trading volume of 25,525 shares. The company’s market cap stands at $88.23 million.

For more information, visit the company’s website at

Dynagas LNG Partners LP (DLNG) is “One to Watch”

According to a past article on MarketWatch (, after the Fukushima nuclear disaster there was an increase in liquefied natural gas (LNG) demand in 2012. This meant that the LNG carrier fleet was operating at a 98% utilization rate. These numbers eventually decreased due to the delay of several liquefaction projects and slowing LNG demand in Asia, but things have since been looking up. Australia and North America will see the addition of significant liquefaction capacity over the next few years. According to the original article, this is expected to increase spending on LNG carriers for supply transportation, with a market boost due to the need for more flexibility in the LNG fleet.

For companies such as Dynagas LNG Partners LP (NYSE: DLNG), this is good news. The company is a growth oriented partnership that operates liquefied natural gas carriers employed on multi-year charters. As well as conventional LNG shipping, DLNG aims to focus its efforts on a fleet that is equipped for trading flexibility, including some of the coldest, sub-zero areas in the world.

Most recently, the company released its results for the third quarter of 2016, showing an increase of distributable cash flow from $23 million during the first three months to over $68 million in the nine months ended September 30, 2016. Not only this, net income rose from just over $17 million to $51.4 million in less than a year, with adjusted net income coming in at just under $57 million in the first nine months of 2016. Earnings per common unit grew from $0.44 to $1.30 in the six-month period, and adjusted earnings per common unit went from just under $0.50 to $1.45.

The company also entered into a new long-term charter agreement with Gazprom Marketing & Trading Singapore Pte Ltd. The agreement allows DLNG to employ the company’s 2007-built 150,000 cbm steam turbine LNG carrier, Clean Energy. This new partnership is expected to start in mid-2018 and continue for a duration of seven years and nine months. During this period, the agreement is expected to generate over $130 million in gross contracted revenues.

In addition to the above, the partnership agreed to cut down the charter hire rate on two existing contracts, Yenisei River and Lena River, both of which were built in 2013. As of this month, the contracted revenues will be reduced by just under $9 million for the Yenisei River and closer to $10 million for the Lena River over the remainder of the current charter terms. CEO of the partnership, Tony Lauritzen, reported that these new charter arrangements increase the partnership’s contracted backlog to around $1.6 billion.

According to a recent article published by Engelwood Daily (, Wall Street released predictions that DLNG’s earnings per share will be $0.41 by the time the company releases its earning at the end of February 2017. Price targets released by Wall Street range from $9 to $18, and, according to the ABR ranking, where one represents a ‘Strong Buy’ and five is a ‘Strong Sell’, the company now has an ABR of two, representing a ‘Buy’ rating.

For more information, visit the company’s website at

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is “One to Watch”

November 28, 2016

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, recently reported its third quarter financial results ( for the three months ended September 30, 2016. CRBP reported a net loss for the third quarter due to increased spending on clinical studies for systemic sclerosis and CF, plus increased staffing costs, bonuses, and other expenditures.

However, the company ended the third quarter with just under $19 million in cash and cash equivalents, which it believes to be sufficient to meet its operating and capital requirements through the end of 2017. The company is also expecting a milestone payment by the end of the first quarter of 2017 from Cystic Fibrosis Foundation Therapeutics, Inc. of $1.5 million.

In addition to its financial results, the company provided an update on its corporate progress and progress on the clinical status of its lead product candidate Resunab, a synthetic oral endocannabinoid-mimetic drug that targets chronic inflammation and aims to stop fibrosis. The drug is currently being tested in three separate phase 2 clinical studies.

Since the release of these financial results, the company completed its phase 2 trials of Resunab in patients with systemic sclerosis, releasing positive data and leading shares to skyrocket. According to CRBP’s findings (, the median patients taking Resunab saw their combined response index in diffuse cutaneous systemic sclerosis score increase by just under 35%, compared to 0% for those taking a placebo.

As a result, Corbus Pharmaceuticals is now seeking approval for the drug from the FDA. The company is also testing Resunab in other phase 2 trials for diseases such as lupus, fibrosis, and dermatomyositis, while patients from the systemic sclerosis phase 2 trials will enter an extension study to measure the drug’s long term effects.

Corbus Pharmaceuticals Holdings also received a company update from Aegis Capital Corp. (, which maintained the company’s ‘Buy’ rating with a price target of $12 per share. This report was based on the strong data released regarding the phase 2 trials in patients with systemic sclerosis.

Other companies such as Noble Financial and Cantor Fitzgerald also reiterated a ‘Buy’ rating for the company, with price objectives of $19.00 and $17.00, respectively. In addition to the above, Barbara White acquired 38,000 shares of CRBP worth $119,700, and CFO Sean F. Moran acquired 148,960 shares worth just under $500,000, all according to The Cerbat Gem Market News and Analysis (, giving insiders just under 12% ownership of CRBP’s stock.

Other large investors have also raised their stakes in the company. Morgan Stanley raised its position in Corbus Pharmaceuticals Holdings, Inc. by 12.4%, Northern Trust Corp. raised its position by 41%, BlackRock Institutional Trust Company N.A. raised its position by 14.3%, and Milestone Group, Inc. and Bank of New York Mellon Corp. bought new positions worth $102,000 and $155,000, respectively. Outside investors now own 25.39% of CRBP’s stock.

For more information, visit the company’s website at

ClearOne, Inc. (CLRO) is “One to Watch”

ClearOne, Inc. (NASDAQ: CLRO), a company that designs, develops, and commercializes conferencing, collaboration, and network streaming and signage solutions for voice and visual communications, recently announced its quarterly earnings, reporting a $0.22 earnings per share for the third quarter of 2016.

Although slightly lower than during the same period of the previous year, ClearOne reported revenue of $12.9 million for the quarter with a net margin of 9.78% and a return on equity of 8.5%. Gross profit for the third quarter of 2016 came in at $7.7 million, with net income of $1.2 million and a non-GAAP net income of $2.0 million.

In addition to the above, a number of hedge funds and other investors opened new and increased stock positions in the company. In particular, Wellington Management Group LLP raised its stock position in CLRO by just under 18%, giving it a 7.72% ownership stake of ClearOne, Inc. worth just over $8 million.

According to an article on The Cerbat Gem Market News and Analysis website (, Morgan Stanley and Northern Trust Corp. raised their positions in shares by 373.8% and 1.9%, respectively, giving them both stakes worth more than $100,000. Vanguard Group, Inc. also raised its position in shares of CLRO by 0.4%, giving it shares of the company’s stock worth more than $1.5 million. As a result of these new and increased stock positions, hedge funds and other investors now own just under 19% of the company, with CLRO Director Larry Hendricks buying shares valued at $232,554.

ClearOne also recently announced that it will be paying a quarterly dividend to investors of $0.05. This adds up to a $0.20 yearly dividend, giving the company a dividend payout ratio of 37.74%. The company has also been the topic of several recent research reports.

The Cerbat Gem Market News and Analysis site referred to above also reported that, while The Street recently lowered shares for ClearOne from a ‘Buy’ rating to a ‘Hold’ rating, Zacks Investment Research upgraded the company’s rating from ‘Hold’ to ‘Buy’ with a target price of $13. In addition, B. Riley gave the company a ‘Buy’ rating with a target price of $13.25. Lastly, Singular Research also gave the company a ‘Buy’ rating with a price objective on its stock of $14.50.

Finally, ClearOne has also now entered into a new distribution agreement with National Source AV whereby National Source AV will represent ClearOne’s media collaboration, UC voice portfolios, and video conferencing to a variety of consultants and other potential stakeholders across Canada.

For more information, visit the company’s website at

Brekford Corp. (BFDI) is “One to Watch”

Calvert County, Maryland, has been working with Brekford Corporation (OTCQX: BFDI), a company in the business of producing and commercializing state-of-the-art public safety technology and automated traffic enforcement solutions for a variety of industries, including the military, U.S. government, and municipalities, among others. The arrangement was put in place in order for Brekford to provide and maintain traffic cameras now placed outside of schools and other facilities.

Since the new installments were put in place, Calvert County has completed the warning period and begun issuing violation notices. Brekford has deployed its seventh red light enforcement system in New Rochelle, New York. Twelve of these photo enforcement systems have been approved by the State of New York with approximately 40 approaches. Brekford is responsible for working with New Rochelle representatives to provide complete coverage in the coming months.

Looking further afield, the company terminated an exclusive distribution agreement with its Mexico-based partner, but started discussing the potential for a direct agreement with the city of Saltillo, Mexico. Other cities in Mexico have shown an interest in implementing photo enforcement programs using the company’s technology. BFDI also recently won competitive solicitation with a federal agency for a five-year contract.

In addition, in May of this year, BFDI announced that it filed a provisional patent application with the United States Patent and Trademark Office (USPTO) regarding technologies associated with the automated detection and photo enforcement of electronic distracted driving violations. The company is continuing to explore a variety of methods that could further enhance traffic safety across the areas it serves.

Following this, Brekford Corp. announced its financial results for the third quarter of 2016 (, reporting a gross profit margin increase to 22.9%, as compared to 15.4% in the same period of the previous year. The gross margin of the company’s ATSE (automated traffic safety enforcement) services products area increased by approximately 8%, and vehicle services gross margin nearly doubled since last year. Despite overall loss having increased by approximately $20,000, operating expenses decreased by $60,000 this year, and operating income increased from $6,350 in 2015 to $56,523 in 2016.

For more information, visit the company’s website at

Conatus Pharmaceuticals, Inc. (CNAT) is “One to Watch”

November 22, 2016

Conatus Pharmaceuticals, Inc. (NASDAQ: CNAT), a biotechnology company focused on the development and commercialization of new medicines to treat a variety of liver diseases, recently announced its financial results for the third quarter of 2016 ended September 30. The company reported no revenue, as it is still in the clinical development stage.

As a result, focus has been on the development of its lead compound, Emricasan, an orally active pan-caspase protease inhibitor that should reduce the activity of human caspases, the enzymes that mediate inflammation and apoptosis. CNAT believes that by reducing the activity of these enzymes, its compound, Emricasan, can interrupt the progress of liver disease and provide potential treatments.

In terms of financial results, the third quarter earnings loss was in-line with street estimates, and cash on hand stands at approximately $31.1 million, which the company believes is enough to maintain operations throughout 2017. Although net loss was slightly higher than this time last year, research and development, administrative, personnel, consulting, legal, and accounting expenses were up due to the progression of the company’s ENCORE program.

This month, the company initiated a randomized, double-blind, placebo-controlled phase IIb clinical trial called ENCORE-PH, which will show results after 24 weeks of twice-daily treatments with Emricasan. Two other ongoing Emricasan phase IIb clinical trials include POLT-HCV-SVR and ENCORE-NF. All phase IIb clinical trials evaluate the potential improvements in various forms of fibrosis and steatohepatitis, as well as the effects Emricasan.

A number of analysts have now published positive reports on Conatus Pharmaceuticals. Zacks Investment Research upgraded the company from ‘Hold’ status to ‘Buy’, while several other research firms offered CNAT an ‘Outperform’ status and upped their price targets on shares. Price targets range from $6 to $16.

Aegis Capital Corp. ( published a company update report giving Conatus Pharmaceuticals a ‘Buy’ rating with a price target of $7. This was based on the fact that the company’s EPS is in line for the third quarter of 2016, in addition to the announcement of the ENCORE-PH trial initiation earlier this month.

Several large investors have made changes to their positions in the company’s stocks, according to an article on the Cerbat Gem Market and News Analysis ( website. The article reports that KCG Holdings, Inc. bought a new stake in shares during Q3 2016 worth $135,000, and that E. Shaw & Co. and Bank of New York Mellon Corp. upped their stakes in shares by over 94% and 2%, respectively. Courage Capital Management LLC also bought a new stake in shares worth $200,000, while Vanguard Group, Inc. boosted its stake in shares by over 3%.

For more information, visit the company’s website at

Cogint, Inc. (COGT) is “One to Watch”

November 21, 2016

Distilling complexity into actionable intelligence is the core focus for recently rebranded data analytics outfit Cogint, Inc. (NASDAQ: COGT). Cogint rang the NASDAQ bell ( only a handful of days after transitioning shares over to the exchange, amid a big push by the company to secure and expand an increasingly dominant footprint in massive scale, people-based digital marketing and customer acquisition solutions via its Fluent ( subsidiary. Fluent is a data-driven performance marketing suite powered by the same proprietary, next-gen data fusion platform known as CORE™, which also powers the company’s analytical and risk management solutions.

Fluent is changing the laws of marketing with a suite of tools that enable the company’s clients to serve personalized, targeted ads and acquire extremely loyal brand customers by leveraging user-generated responses and real-time interactivity. With digital display ad spending overtaking search ad spending this year for the first time in history – as the biggest categories like video, rich media and banners take up approximately half the $32 billion plus pie ( – a hyper-targeted and user-centric digital marketing/customer acquisition and retention solution like Fluent finds itself in an advantageous position when it comes to distinguishing itself.

Over 500 leading brands, such as online home improvement marketplace BuildDirect, Finish Line (NASDAQ: FINL) and Western Union (NYSE: WU), already trust Fluent to deliver the goods, and have come to rely upon the industry-leading data acquisition, mobile app install and performance display ad solutions located within the suite. BuildDirect, for instance, saw a 25 percent jump in user engagement thanks to Fluent’s ReConnect™ solution for supercharging an email marketing program.

One secret to Fluent’s success in this arena is the immense reservoir of proprietary consumer data that the company already has at its fingertips. The marketing suite is empowered by an enviable feedback loop with the consumers themselves, consisting of over 700,000 direct user interactions, six million survey responses, and more than 1.2 million ad responses per day. A brand looking to do consumer marketing through mobile user acquisition/retention, other audience engagements tool and data acquisition has a powerful over-the-horizon radar system in Fluent. And the platform has a proven track record of being able to produce tangible results, relying to a great extent on the unprecedented precision of the platform’s user-driven targeting matrix.

The company plans to dramatically increase the size and scope of Fluent’s business moving forward (, using a combination of diligent retargeting of pre-qualified audiences across all connected device types, and the enabling of mobile display, search, social, video and eventually addressable television campaigns. This is where Cogint’s Q Interactive ( subsidiary really shines, as a direct publisher crafting tailored lead generation for digital, performance-based campaigns – and one which is squarely focused on maximizing advertiser’s return on investment. Q Interactive works hand-in-hand with advertisers to hone the target matrix of ideal consumer profiles down to the ideal level, exploiting the company’s enormous user engagement envelope to intelligently place a given brand, product or service directly in front of those most receptive to it. At the same time, Q Interactive is able to drive high quality traffic generation by being able to offer publishers first rate monetization for the best traffic. Q Interactive’s various promotions, coupons, sample campaigns and the like are some of the most lucrative monetizing properties online today.

Again, at the center of all this is a cloud-based custom data analytics backbone engineered from the ground up to handle any kind of data type (such as behavioral and demographic, or transactional), and deliver actionable intelligence that is suitable to any industry. Actually the fusion of CORE and the company’s Agile Acquisition Engine™, this same technology backbone that enables complex digital performance marketing tasks also enables COGT to offer its clients the ability to do extremely in-depth investigative work. Tasks such as fraud detection/prevention, identity verification, regulatory compliance, and location (skip) tracing are a breeze for Cogint’s IDI (Interactive Data) subsidiary and its idiCORE ( investigative solution. This is really worth taking into consideration when you look at a report like the one out of IDC last month, which not only projected that big data and analytics would go more mainstream in coming years, but that the market is on track to top $203 billion by 2020 (

While similar data fusion architectures may exist, they are costly and largely outdated. On the other hand, idiCORE is an extremely efficient (and therefore less expensive) system, which is able to yield higher-fidelity data and at a lower cost. The idiCORE platform utilizes proprietary linking technology (algos/logic) and machine learning principles which, when paired with the company’s massive data repository (that includes credit header data, public records, private/proprietary sources and more), allows for superb relational resolutions, whether one is looking at connections, individual people, or assets. And idiCORE has an impressive pedigree too, being the next-gen data fusion solution that stands on the shoulders of data fusion pioneer Hank Asher’s work. Asher was the architect behind market heavy hitters Accurint® ( (now owned by LexisNexis, RELX Group) and TLOxp® (, now owned by TransUnion (NYSE: TRU).

CEO and Interim President of COGT, Derek Dubner, worked closely with Asher (regarded by many as the father of data fusion) for 15 years and was general counsel to TLO, from its inception through to its eventual sale to TransUnion. Dubner was quite proud of idiCORE’s recent successes during COGT’s Q3 earnings call (, where he highlighted the addition of key foundational datasets, including a gigantic database of motor vehicle records to idiCORE, as well as the platform’s improved data sorting features.

Most noteworthy among the quarterly data release is a 27 percent revenue uptick to $52.2 million ( (compared to Q2), with performance marketing having accounted for the lion’s share of revenues at around 70 percent. Dubner also threw a spotlight on the ongoing expansion of the company’s cutting-edge idiCORE investigative solution, particularly as it relates to Cogint’s risk management division, before touting the enhanced search functionality and accuracy idiCORE now possesses.

It’s no wonder the company recently tapped two industry veterans to join the team. Harry Jordan came on board as COO in early August ( and brought two decades with outfits like LexisNexis along, including a wealth of experience in M&A that led to such landmark deals as the ChoicePoint and Seisint acquisitions. Twenty-year industry veteran Jeff Dell was appointed CIO in mid-September ( A natural transition from the same roles Dell played at TLO and Seisint, roles which uniquely prepared him to be the top information security professional for COGT, as the company expands and looks to continue increasing security.

Dubner was keen to point out in the Q3 earnings call that there was a whopping 400 percent CAGR for Q3 when it comes to the number of online transactions done using idiCORE. It’s very exciting statistic about how ingrained this intuitive solution has already become among end markets, as well as being a positive sign about the raw, overall platform adoption rates. Additionally, Dubner cited the abnormally high number of contract versus transactional usages seen thus far with idiCORE, remarking how odd it was for a new product on launch. It’s a very positive sign indeed, as it indicates end users are having a very good reaction to the solution, from both usability and intuitiveness standpoints.

Wringing actionable intelligence from the complex web of information requires a database-spanning fusion engine such as idiCORE. This data fusion engine can deliver the kind of penetrating investigative and risk management capabilities needed to map and study the intricate connections between even seemingly disparate data points like assets, businesses, or people – and idiCORE can do it all in real-time.

To learn more about Cogint, visit

CytoSorbents Corp. (CTSO) is “One to Watch”

November 18, 2016

November has been a promising month for CytoSorbents Corp. (NASDAQ: CTSO), a critical care immunotherapy company. The New Jersey-based company, specializing in blood purification to control deadly inflammation in critically ill and cardiac surgery patients, reported its financial results for the third quarter ended September 30, 2016.

CTSO reported that product sales for the third quarter of this year were up to $2.14 million, a new record, marking the sixth quarter in a row to show substantial growth with sales up by 100% from 2015’s $1.07 million. The jump was attributed to increases in both direct sales and sales through distributors.

Total revenue for the third quarter of 2016, including product sales and grant revenue, came in at $2.4 million, marking an overall gross margin of $1.4 million compared to $0.7 million in the third quarter of 2015. In addition, product gross margins for the third quarter of 2016 were approximately 5% higher than in the same quarter of 2015.

As a result, Aegis Capital Corp. upgraded its CytoSorbents estimates, offering the company a ‘Buy’ rating with a target price of $20. The report states: “CTSO reported revenues of $2.41 million versus consensus of $2.21 million and our $2.25 million estimate.” The report also highlighted that Aegis expects further acceleration through 2017.

Highlights from the report include the growth of CytoSorb sales of 13,000 units, the fact that REFRESH 1 met its safety endpoint, and that CytoSorbents has $6.4 million in cash with $5 million available from its credit facility with Bridge Bank. As a result, the company expects to have enough funding for its operations through the second half of 2017.

CytoSorbents’ Q3 2016 sales report is not the only aspect of the company’s recent success. In November of this year, CTSO announced the addition of Belgium and Luxembourg to its direct sales directories, expanding its distribution to include 42 countries around the world. These new additions will allow CytoSorbents to target these focused markets with its own direct sales force.

For more information, visit the company’s website at

Nektar Therapeutics (NKTR) is “One to Watch”

November 17, 2016

Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical company in the business of developing new medicines for people living with life changing conditions, now helps more than nine million patients worldwide. Nektar also offers a proprietary pipeline made up of drug candidates for oncology, pain, anti-infectives, and immunology. The company has 12 approved products, including Movantik, Adynovate, and Onzeald.

Movantik, which is used for the treatment of opioid induced constipation, was approved for sale in both the U.S. and Europe in 2014, allowing Nektar to see a significant increase in sales and royalty payments. Adynovate, used in the treatment of hemophilia A in patients aged 12 and above, was approved for sale in the U.S. in 2015. The company also partnered with Shire, giving Nektar an extra $55,000 in sales.

Onzeald is used in the treatment of metastatic breast cancer with brain metastases. The company partnered with Daiichi Sankyo on June 1, 2016, giving Daiichi exclusive commercialization rights in the European Economic Area, Switzerland, and Turkey. This partnership could potentially give Nektar a total of $60 million in commercial and regulatory milestones.

In addition, Nektar Therapeutics recently presented new clinical data ( from its ongoing phase I dose-escalation study of NKTR-214 at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting. The candidate is an investigatory immunostimulatory therapy that expands specific cancer fighting T-cells and natural killer cell abundance in the tumor’s microenvironment.

According to Dr. Ivan Gergel, Senior Vice President, Drug Development & Chief Medical Officer of Nektar, “NKTR-214 resulted in robust activation of the immune system and encouraging anti-tumor activity, including a partial response observed in a patient who continues to be treated with NKTR-214”. There has been evidence that seven out of the 18 patients so far have had radiographic reductions in tumor size per RECIST 1.1 on NKTR-214.

With this in mind, Aegis Capital Corp. ( initiated coverage on Nektar Therapeutics, offering the company a ‘Buy’ rating with a target price of $21. Areas covered in the report include the sources of revenue, details of the partnerships put in place, and an oncology clinical collaboration with BMS for evaluating the combination of Opdivo and NKTR-214. The target price was based on an EV/Sales multiple of eight, which was applied to the expected sales of $378 million by 2020.

For more information, visit the company’s website at

GainClients, Inc. (GCLT) is “One to Watch”

November 14, 2016

GainClients, Inc. is a software service company focused primarily on the development of marketing services for real estate professionals and valuable home search and area information tools for consumers. The company’s innovations expound the popularity of online networks by helping real estate professionals better serve their clients through the sharing of accurate real estate data.

The company’s main product is the GCard progressive networking system, which is designed to build and promote relationships among real estate professionals and their clients. Using the GCard, agents and brokers have the means to offer real estate, lending and title services information through an integrated, web-based network, capitalizing on the ongoing shift in consumer preference toward mobile solutions.

Similar to the features of other popular online networks, professional users can invite clients and their industry partners to join their GCard networks and be featured as trusted team members. From here, the teams can quickly provide real estate, lending and title services and information to consumers via smartphone and web. With better communication throughout the process of buying or selling homes, purchases can move more quickly and more comfortably to completion.

Strategic partnerships are an important component of GainClients’ growth strategy. The company recently established a worldwide licensing arrangement with CLOVIS LLC, a partnership that will enable the distribution of both companies’ proprietary technologies to the real estate industry. CLOVIS will use GainClients’ GCard to develop a unique lead generation program for the broader real estate marketing and advertising industry.

GainClients also offers GCHomeSearch, its stand-alone website that provides non-real estate customers, such as lenders and title professionals, with accurate listing data, historical property data, neighborhood information and demographics. When used with the GCard, the user is also privy to loan payment calculators, loan rates, closing cost estimators and other tools needed to make intelligent buying and selling choices.

For more information, visit the company’s website at

Let us hear your thoughts: GainClients, Inc. Message Board

Trevena, Inc. (TRVN) is “One to Watch”

November 11, 2016

Trevena, Inc. (NASDAQ: TRVN) is a clinical stage biopharmaceutical company focused on developing and delivering biased ligands to discover the next generation of GPCR targeted medicine. The company is focused on three product candidates:

  • Oliceridine, for moderate to severe acute pain;
  • TRV734, an oral use medicine for people in moderate, severe acute, and chronic pain;
  • and TRV250, for those suffering from migraines.

On November 7, 2016, Aegis Capital Corp. ( initiated coverage on Trevena, Inc., offering the company a ‘Buy’ rating with a target price of $14. This rating was released soon after the company reported its third quarter 2016 financial results alongside a corporate update. In the press release, CEO Maxine Gowen reported important progress for the quarter ending September 30, 2016.

According to Trevena’s third quarter report, top-line data from its APOLLO-1 and APOLLO-2 phase III efficacy trials of Oliceridine is on track for release in the first quarter of 2017, and the patient enrollment remains on track in the ETHENA multi-procedure safety study of Oliceridine to support an NDA filing in 2H 2017. Trevena, Inc. also announced that its TRV250 program is on track for IND submission this year.

The company has reported continued engagement at pain medicine conferences, and has hosted an investor webcast featuring presentations on acute pain management by leading clinicians.

Out of the seven analysts who have covered Trevena this year, six rated the company at ‘Buy’ and one at ‘Hold’. In the first weeks of November, Trevena has reported a stock price increase of roughly 50 percent to $5.75 per share as of November 11, an increase of $1.94 per share from its November 3 PPS.

For more information, visit the company’s website at

Celldex Therapeutics, Inc. (CLDX) is “One to Watch”

Last month, Celldex Therapeutics, Inc. (NASDAQ: CLDX), a company in the business of developing targeted therapeutics for those suffering from devastating diseases for which current treatments are inadequate, found positive results from its phase II study of glembatumumab vedotin in patients with stage III/IV checkpoint inhibitor-refractory. The study showed that patients experienced a confirmed response, with 52% of patients experiencing tumor shrinkage. In addition, by close of market on November 8, 2016, Celldex stock was up significantly as investors reacted to the company’s third quarter earnings report, which surpassed estimates for revenue and EPS. CLDX’s stock rose by nearly 15% to close at $3.78 on 9.01 million shares, more than four times the company’s average.

Aside from its recent growth, Celldex announced the acquisition of Kolltan Pharmaceuticals, Inc. on November 1. Kolltan is a privately owned clinical-stage company that develops new antibody-based drugs and is worth $62.5 million in stock. “Celldex believes Kolltan’s clinical candidates and preclinical platform are highly compatible with the Company’s scientific approach and can be developed independently and in combination with Celldex’s existing product candidates,” according to a statement shared on the Scibility Media website (

On November 7, Aegis Capital Corp. ( initiated coverage on Celldex Therapeutics, Inc., giving the company a ‘Buy’ rating and a target price of $10. In addition, as of November 8, 2016, ClosingBell Active Analyst Ratings ( gave CLDX an average stock rating of 3.6 on a one to five scale, with five denoting ‘Buy’ and one indicating ‘Sell’. The numbers above are predicted to allow Celldex Therapeutics, Inc. to fund its operations through 2018.

For more information, visit the company’s website at

KaloBios Pharmaceuticals, Inc. (KBIO) is “One to Watch”

October 27, 2016

With more people across the U.S. faced with the unpleasant fact that healthcare and pharmaceutical costs are exceptionally high and continuing to grow, KaloBios Pharmaceuticals, Inc. (OTC: KBIO) is taking a step closer to positive change with new, innovative, and responsible pricing models.

The company is leading a new way of thinking regarding how medicines are priced, and how to tackle neglected and rare diseases. KBIO is advancing treatments and medicines for patients through innovative and responsible business models, leading by example with concrete operational changes, such as its Responsible Pricing Model.

This model was recently recognized in an article entitled ‘Will Investors Reward Drugmakers That Limit Price Increases?’ by Medical Marketing & Media ( The article highlights the problems that healthcare systems are facing, with the Epipen as an example, voicing a common professional medical investor fear that “this parade of pricing scandals makes us look like a pack of scoundrels. Sure, the EpiPen is a marvel. But that doesn’t mean it should be unaffordable! For a small number of patients, Daraprim can be life-saving. But that shouldn’t mean you should hike its price overnight by 50-fold!”

The article continues with an explanation of KaloBios’ new incentive to confine its revenue expectations to a “reasonable return.” With this in mind, KaloBios believes that, to achieve real transformation in the way the healthcare system operates as well as among patients and stakeholders, transparency and collaboration are key.

KaloBios Pharmaceuticals, Inc. is in the business of developing therapeutics for the treatment of cancer in the United States. The company’s Responsible Pricing Program means it is affordable to patients while maintaining a reasonable and transparent profit margin. KBIO does not make arbitrary price increases on its products, and keeps a close eye on inflation and the Consumer Price Index (CPI).

For more information, visit the company’s website at

Galectin Therapeutics, Inc. (GALT) is “One to Watch”

September 29, 2016

Fibrosis is when connective tissue from an injury or other circumstances thickens and scars, or when there is excess fibrous connective tissue in an organ after it has been exposed to a chronic disease. Unfortunately, the effects of fibrosis cannot be reversed, and there is currently no treatment that stops the disease from getting worse, although some treatments can deal with the symptoms temporarily.

Galectin Therapeutics, Inc. (NASDAQ: GALT) is currently undertaking its phase 2a pilot trial (NASHFX) with GR-MD-02 in non-alcoholic steatohepatitis (NASH) patients with advanced fibrosis. Although the study did not meet original expectations, Galectin’s larger scale, one year trial in patients with NASH cirrhosis has already enrolled 162 subjects, and top line results will be reported by the end of December 2017. The company considers it encouraging to see that GR-MD-02 has an important clinical effect in both moderate and severe cases of psoriasis. This further suggests that the substance can play a role for human diseases that could be related to NASH.

Galectin Therapeutics, Inc. is a biotechnology company focused on the science of galectins, a family of proteins, and drug development. With this expertise, the company creates new therapies for patients suffering from fibrotic diseases and cancer. Galectin works with a variety of partners in order to achieve cost effective and efficient development results within short time frames.

GALT is currently looking to enhance and market its lead compounds in liver fibrosis and cancer immunotherapies. The company has three key areas of focus: studying galectins, developing proprietary compounds for diseases, and advancing its discovery programs. All three work together in order to achieve the overall goal of creating new therapies for fibrotic diseases and cancer.

For more information, visit

Horizon Pharma plc (HZNP) is “One to Watch”

September 22, 2016

Headquartered in Dublin, Ireland, Horizon Pharma (NASDAQ: HZNP) is a biopharmaceutical company whose aim is to improve lives with the recognition, development, acquisition, and commercialization of accessible medicines to meet a variety of patient medical needs. Horizon Pharma now markets nine key products through its orphan, rheumatology, and primary care business units.

Products include ACTIMMUNE®, Buphenyl®, Duexis®, KRYSTEXXA®, Migergot®, PENNSAID® 2%, Ravicti®, Rayos®, and Vimovo®. These products are used to reduce the frequency and severity of serious infections, treat patients with urea cycle disorders, relieve signs and symptoms of rheumatoid arthritis and osteoarthritis, decrease the risk of developing upper gastrointestinal ulcers, and treat patients with chronic gout, among other symptoms and diseases.

In October 2014, HZNP acquired PENNSAID® 2%, followed by Hyperion Therapeutics in May 2015. At the beginning of this year, the company completed the acquisition of Crealta Holdings LLC, which allowed it to expand its orphan business with KRYSTEXXA® (pegloticase), a biologic medicine for chronic, refractory gout.

In addition, Horizon Pharma recently entered into a definitive agreement with Raptor Pharmaceutical Corp. (NASDAQ: RPTP), through which HZNP will acquire all of the issued and outstanding shares of RPTP common stock for a cash payment of $9.00 per share. The transaction is expected to be completed by the end of 2016 and is estimated to be worth $800 million.

Horizon Pharma has approximately 890 global employees and operates across Ireland, Europe, and the United States. As of August 9, 2016, Horizon Pharma had a market capitalization of $3.60 billion. The company has seen steady growth in net sales and adjusted EBITDA. With net sales up from $74 million in 2013 to over $1 billion in 2015, HZNP expects to strengthen its focus on rare diseases while expanding further into Europe and other international markets.

For more information, visit the company’s website at

Vycor Medical (VYCO) is “One to Watch”

August 30, 2016

Vycor Medical (OTCQB: VYCO) provides the medical world with new, unique therapeutics, neurosurgical and neurotherapeutic solutions. The company designs, manufactures and sells FDA-cleared medical devices alongside its computer-based light simulation therapies for the visibly impaired resulting from neurological trauma such as strokes. Vycor Medical is made up of a range of therapies and systems including: the ViewSite Brain Access System (VBAS), the NovaVision Restoration Therapy (VRT), the Sight Science Neuro-Eye Therapy (NeET), and the NovaVision NeuroEyeCoach (NEC).

Vycor Medical is committed to providing the best solutions and therapies in the market, with the aim of making neurosurgical brain, spinal and surgical procedures safer and more effective. All of the company’s products are built with one core goal in mind: increased safety. To do this, each product has been designed to optimize site access, reduce risks for patients, speed up the recovery process, and to add value and quality to the medical world.

Most recently, Vycor Medical reported its financial results for the three and six months ended June 30, 2016. The company’s revenue for the first quarter of this year was $379,000, up from $286,000 during the same period of 2015. Revenue for the Vycor division was also up by over 50%, and reports of patients starting NovaVision therapy were also up by more than 50% compared to 2015. The company reported expenditures to be 59% lower than in 2015 and non-GAAP net loss was nearly a quarter of the amount in 2015.

Vycor Medical’s revenues for the six months before June 30, 2016, were up by more than $150,000 compared to 2015. Revenues for the Vycor division and new patient starts in NovaVision were both up by more than 40%. Expenditures for the company were halved compared to 2015, as was the non-GAAP net loss. The company plans to continue growing its two businesses while maintaining low costs, with Vycor Medical decreasing expenditures and focusing its NovaVision attention on a direct-to-patient website and social media efforts.

For more information, visit


Select A Month
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Search


    Select A Category
  • 21st Century Holding Company TCHC (1)
  • 5BARz International Inc. BARZ (12)
  • 5G Wireless Communications Inc. FGWC (8)
  • 92 Resources Corp. RGDCF (15)
  • A.P. Pharma Inc. APPA (3)
  • Abazias Inc. ABZA (2)
  • ABcann Global Corp. ABCCF (29)
  • ABV Gold ABVG (11)
  • ACME Sports & Entertainment Inc. ASEN (2)
  • Adaptive Medias Inc. ADTM (6)
  • Advanced ID Corp. AIDO (5)
  • Advanced Medical Isotope Corp. ADMD (10)
  • Advanced Resources Group Ltd. AVRG (3)
  • Advanced Viral Research Corp. ADVR (9)
  • Advanced Visual Systems Inc. AVSC (10)
  • Advanced Voice Recognition Systems Inc. AVOI (11)
  • Advanced Wound Technologies Inc. AWTM (4)
  • Advaxis Inc. ADXS (2)
  • Agora Holdings Inc. AGHI (33)
  • Ahead of the Bulls (1)
  • AISystems, Inc. ASYI (11)
  • Aladdin Trading & Company ADTD (29)
  • Algae Dynamics Corp. ADYNF (31)
  • All American Gold Corp AAGC (13)
  • All Asia Licensing Inc. AASI (1)
  • ALL Fuels & Energy Company AFSE (49)
  • All Grade Mining Inc. HYII (3)
  • All Penny Stocks (3)
  • Allarae Healthcare Inc. ALHI (5)
  • Alliance Creative Group ACGX) (15)
  • Alliance Recovery Corp. ARVY (34)
  • Alltemp, Inc. LTMP (1)
  • APTD (2)
  • Alpine TLI Group Inc. APGR (7)
  • ALR Technologies Inc. ALRT (9)
  • Alternative Construction Technologies Inc. ACCY (10)
  • Alternative Energy Development Corp. ADEC (1)
  • Alternative Fuel Technology Inc. AFTC (1)
  • Alternet Systems Inc. ALYI (47)
  • AM Oil Resources & Technology Inc. AMOR (8)
  • Amarin Corp. AMRN (2)
  • Amaru Inc. AMRU (2)
  • Amerex Group, Inc AEXG (16)
  • American Capital Partners Inc. APRJ (1)
  • American Fiber Green Products Inc. AFBG (1)
  • American Oriental Bioengineering Inc. AOB (3)
  • American Racing Capital Inc. AMRA (2)
  • American Software (2)
  • Amgen Inc. AMGN (2)
  • AmMex Gold Mining Corp. AMXG (2)
  • Ampex Corp AMPX (1)
  • AnalytixInsight Inc. ATIXF (18)
  • Andover Medical Inc. ADOV (2)
  • Angstrom Microsystems Inc. AGMS (46)
  • Apolo Gold and Energy Inc. APLL (1)
  • Apple Inc. AAPL (13)
  • AppSwarm, Inc. SWRM (33)
  • Aquasil International Inc. AQUS (3)
  • Armco Metals Holdings Inc. AMCO (36)
  • AspenBio Pharma APPY (1)
  • Assured Pharmacy Inc. APHY (1)
  • Asta Funding Inc. ASFI (2)
  • Atlantic Energy Solutions Inc. AESO (1)
  • ATSI Communications Inc. ATSX (1)
  • Augme Technologies Inc. AUGT (70)
  • Auric Mining Corp. AUMY (3)
  • Automated Vending Technologies Inc. AVTC (3)
  • Automotive Company GNAU (11)
  • AV1 Group, Inc. AVOP (10)
  • Avalon Oil and Gas Inc. AOGN (16)
  • Avant Diagnostics Inc. AVDX (29)
  • Avatar Systems Inc. AVSY (3)
  • Axiom Management Inc. AXMA (3)
  • Axis Technologies Inc. AXTG (2)
  • B2Digital Inc. BTOD (18)
  • Balatia Airlines BLTA (2)
  • Bald Eagle Energy Inc. BEEI (18)
  • Banjo & Matilda Inc. BANJ (8)
  • (4)
  • Beacon Enterprise Solutions Group BEAC (47)
  • Beacon Equity Research (552)
  • Beijing Med-Pharm Corp. BGJP (2)
  • Bergamo Acquisition Corp. BGMO (15)
  • Big Tree Group Inc. BIGG (36)
  • Bio-Clean International Inc. BCLE (1)
  • Bio-Matrix Scientific Group Inc. BMSN (1)
  • BioCentric Energy Holdings Inc. BEHL (1)
  • Biomagnetics Diagnostics Corp. BMGP (3)
  • bioMETRX Inc. BMRX (1)
  • Bionic Products Corp. BNPD (4)
  • Biophan Technologies Inc. BIPH (1)
  • BioSolar Inc. BSRC (22)
  • Biotech Holdings Ltd. BIOHF (3)
  • Inc. BZRT (9)
  • Black Diamond Brands Corp. BDMHF (1)
  • Blue Diamond Ventures Inc. BLDV (1)
  • Blue Moon Zinc Corp. BMOOF (8)
  • Blue Water Global Group Inc. BLUU (7)
  • Blugrass Energy Inc. BLUG (4)
  • Bollente Companies, Inc. BOLC (7)
  • (1)
  • Boreal Water Collection Inc. BRWC (23)
  • Boston Therapeutics Inc. BTHE (20)
  • Bridgetech Holdings International Inc. BGTH (1)
  • Brighton Oil & Gas Inc. BROG (8)
  • Britannia Mining Inc. BMIN (14)
  • Brite Strike Tactical Illumination Products, Inc. BSTI (41)
  • Brookside Technology Holdings Corp BKSD (2)
  • Bullzi Security Inc. BLLZ (3)
  • BWI Holdings Inc. BWIH (165)
  • Cache Elite Inc. ILUS (10)
  • Cal-Bay International Inc. CBYI (6)
  • Callisto Pharmaceuticals, Inc. (1)
  • Calpian Inc. CLPI (27)
  • CAMAC Energy Inc. CAK (2)
  • Canam Energy Inc. CNGJ (10)
  • CanAm Uranium Corp. CAUI (58)
  • Cannabics Pharmaceuticals Inc. CNBX (14)
  • Capital City Energy Group Inc. CETG (18)
  • Car Monkeys Group CKMY (15)
  • Carbon Sciences Inc. CABN (21)
  • CardioVascular BioTherapeutics Inc. CVBT (5)
  • Cardium Therapeutics Inc. CXM (44)
  • Carl Data Solutions Inc. CDTAF (5)
  • Cascade Technologies Inc. CSDT (2)
  • Cascadia Investment Inc. CDIN (4)
  • Casey Corp. CCPR (1)
  • Cashcow Magazine (4)
  • Cavico Corp. CVIC (3)
  • CD International Enterprises, Inc. CDII (48)
  • CDC Corp. CHINA (4)
  • CelebDirect Inc. CELI (3)
  • Cellceutix Corp. CTIX (18)
  • CellCyte Genetics Corp. CCYG (3)
  • Century Group, Inc. CEYG (1)
  • CEOcast (184)
  • CepTor Corp. CEPO (1)
  • Cereplast Inc. CERP (9)
  • Chancery Resources Inc. CCRY (3)
  • Changing Times Vitamins Inc. SGTB (12)
  • CHDT Corp. CHDO (5)
  • Cherubim Interests Inc. CHIT (36)
  • China 3C Group CHCG (13)
  • China America Holdings Inc. CAAH (8)
  • China Direct Inc. CDS (4)
  • China Education Alliance Inc. CEUA (4)
  • China Energy Recovery Inc. CGYV (12)
  • China Growth Development Inc. CGDI (2)
  • China Health Management Corp CNHC (7)
  • China Health Resource Inc. CHRI (14)
  • China INSOnline Corp. CHIO (1)
  • China Jiangsu Golden Horse Steel Ball Inc. CJGH (3)
  • China Logistics Group Inc. CHLO (11)
  • China Media Group Corp. CHMD (2)
  • China Medicine Corporation CHME (5)
  • China Nuvo Solar Energy Inc. CNUV (3)
  • China Organic Agriculture Inc. CNOA (11)
  • China Petroleum and Chemical Corp. SNP (2)
  • China Voice Holding Corp. CHVC (47)
  • China Wind Systems Inc. CWSI (6)
  • China Wireless Communications Inc. CWLC (4)
  • China Yongxin Pharmaceuticals Inc. CYXN (5)
  • China YouTV Corp. CYTV (1)
  • ChinaTel Group Inc. CHTL (1)
  •, Inc. CIIX (111)
  • Choom Holdings Inc. CHOOF (12)
  • ChromaDex Corp. CDXC (3)
  • City Capital Corp. CTCC (2)
  • Cityside Tickets CIST (21)
  • CleanTech BioFuels Inc. CLTH (10)
  • Cleantech Transit Inc. CLNO (3)
  • Clearly Canadian Beverage Corp. CCBEF (13)
  • Cleartronic Inc. CLRI (52)
  • Clenergen Corp. CRGE (37)
  • CMG Holdings Inc. CMGO (2)
  • Coastal Integrated Services Inc. COLV (13)
  • Coil Tubing Technology Inc. CTBG (1)
  • Colorado Goldfields Inc. CGFI (5)
  • Colt Resources Inc. COLTF (13)
  • Columbia River Resources Inc. CRVR (1)
  • CoMedia Corp. CMTN (1)
  • CommercePlanet Inc. CPNE (4)
  • Compress Technologies Inc. CTLG (17)
  • Conforce International Inc. CFRI (2)
  • CAJT (9)
  • Cono Italiano Inc. CNOZ (12)
  • Consorteum Holdings, Inc. CSRH (171)
  • Consorteum Holdings, Inc. CSRH (4)
  • ContentChecked Holdings Inc. CNCK (60)
  • Continental Fuels Inc. CFUL (2)
  • Converde Energy USA Inc. XFUL (12)
  • Convergence Technology Group Inc. CNVC (7)
  • Copper King Mining Corp. CPRK (2)
  • Cord Blood America Inc. CBAI (102)
  • Crdentia Corp CRDT (12)
  • Creative Vistas Inc. CVAS (2)
  • Crystal International Travel Group Inc. CINT (4)
  • Cubic Energy Inc. QBC (2)
  • Cybermesh International Corp. CYTL (1)
  • Cyclone Power Technologies Inc. CYPW (9)
  • CYIOS Corp. CYIO (1)
  • Daily Views (13)
  • Dakshidin Corp. DKSC (5)
  • Data Call Technologies Inc. DCLT (25)
  • Daulton Capital Corp. DUCP (26)
  • Davi Skin Inc. DAVN (1)
  • Debt Resolve Inc. DRV (2)
  • Debut Broadcasting Corporation Inc. DBTB (1)
  • Deep Blue Marine Inc. DPBM (6)
  • Deep Down Inc. DPDW (15)
  • Deer Valley Corp. DVLY (2)
  • Defense Solutions Inc. DFSH (3)
  • Delta Mining and Exploration Corp. DMXC (1)
  • Dermisonics Inc. DMSI (1)
  • Destination Television Inc. DSTV (17)
  • Dhanoa Minerals Ltd. DHNA (4)
  • DigitalPost Interactive Inc. DGLP (8)
  • Document Capture Technologies Inc. DCMT (3)
  • DoMark International Inc. DOMK (29)
  • Dominovas Energy Corp. DNRG (73)
  • Dragon Capital Group Corp. DRGV (11)
  • Dragon International Group Corp. DRGG (2)
  • Duma Energy Corp. DUMA (20)
  • Duska Therapeutics Inc. DSKA (1)
  • Dutton Associates (88)
  • DXP Enterprises Inc. DXPE (4)
  • Dynamic Media Holdings Inc. DYMH (6)
  • Dynamic Response Group Inc. DRGP (6)
  • Dynasty Limousine Inc. DNYS (19)
  • Earth Dragon Resources Inc. EARH (10)
  • Eastbridge Investment Group Corp. EBIG (1)
  • Ebenefits Direct, Inc. EBFD (21)
  • eCareer Holdings Inc. ECHI (9)
  • Echo Therapeutics Inc. ECTE (5)
  • EcoloCap Solutions Inc. ECOS (2)
  • Ecologic Transportation Inc. EGCT (11)
  • Ecosciences Inc. ECEZ (1)
  • Ecotality, Inc. ECTY (67)
  • eCrypt Technologies Inc. ECRY (79)
  • EdgeTech International Inc. EGIL (6)
  • eDoorways Corp. EDWY (183)
  • Inc. EFSF (4)
  • EFuel EFN Corp. EFUL (1)
  • EGPI Firecreek Inc. EFIR (1)
  • Elephant Talk Communications Corp. ETAK (8)
  • Elephant Talk Communications Inc. ETAK (2)
  • Elleipsis Global Travel Solutions Inc. EGTS (3)
  • Elray Resources Inc. ELRA (11)
  • Elron Electronic Industries Ltd. ELRN (1)
  • Emerging Media Holdings Inc. EMDH (22)
  • Empire Energy Corporation International EEGC (3)
  • Endeavor Explorations Inc. EAVR (7)
  • Endeavour Silver Corp. EXK (3)
  • Endevco Inc. EDVC (2)
  • Energtek Inc. EGTK (61)
  • Enherent Corp. ENHT (2)
  • EnterConnect Inc. ECNI (5)
  • Enterprise Oilfield Group Inc. E.TO (13)
  • EnXnet Inc. EXNT (1)
  • Epazz, Inc. EPAZ (48)
  • Equity Stock Analysis (1)
  • ER Urgent Care Holdings Inc. ERUC (6)
  • ERF Wireless Inc. ERFB (15)
  • Essential Innovations Technology Corp. ESIV (2)
  • Inc. ETLC (3)
  • Ethema Health Corporation GRST (7)
  • Euoko Group Inc. EUOK (2)
  • EV Innovations Inc. EVII (189)
  • EV Transportation Inc. EVTP (7)
  • EVIO, Inc. EVIO (33)
  • Exchange Media Corp. EXMD (9)
  • Exeter Resource Corp. XRA (2)
  • eXp World Holdings, Inc. EXPI (81)
  • Expert Group Inc. EXPT (5)
  • ExpressIR Inc. (1)
  • Extreme Motorsports of California, Inc. EMOC (26)
  • ezBanc-A Stocklender's Journal (6)
  • Falcon Crest Energy FCEN (75)
  • Falcon Ridge Development Inc. FCNR (2)
  • Famous Uncle Als Hot Dogs & Grille Inc FDOG (10)
  • FANDOM SPORTS Media Corp. FDMSF (5)
  • Fastfunds Financial Corp. FFFC (17)
  • Financial Media Group, Inc. FNGP (26)
  • Financial Services Exchange FSE (1)
  • First Cobalt Corp. FTSSF (49)
  • First Titan Corp. FTTN (45)
  • FlexWeek Inc. FXWK (11)
  • FluoroPharma Medical Inc. FPMI (46)
  • Foldera, Inc. FDRA (11)
  • Force Energy Corp. FORC (5)
  • FormCap Corp. FRMC (29)
  • Fortune Market Media Inc. FTMM (5)
  • Franklin Mining Inc. FMNJ (1)
  • Freedom Leaf Inc. FRLF (12)
  • Fresh Harvest Products Inc. FRHV (7)
  • Fresh Promise Foods Inc. FPFI (12)
  • Freshstart Properties Inc. FSPP (1)
  • FrogAds Inc. FROG (6)
  • Frozen Food Gift Group Inc. FROZ (5)
  •, Inc. FNDM (56)
  • Fushi Copperweld Inc. FSIN (2)
  • GainClients Inc. GCLT (9)
  • Galenfeha Inc. GLFH (28)
  • Gastar Exploration Ltd. GST (2)
  • Gemini Explorations Inc. GXPI (12)
  • Gen2media Corp. GTWO (2)
  • General Environmental Management Inc. GEVI (56)
  • General Metals Inc. GNMT (1)
  • General Steel Holdings Inc. GSI (3)
  • GeoBio Energy Inc. GBOE (1)
  • GeoEye Inc. GEOY (4)
  • GeoPharma Inc GORX (1)
  • Giggles N’ Hugs Inc. GIGL (90)
  • Global Alumina Corp. GLA.U (1)
  • Global General Technologies Inc. GLGT (1)
  • Global Hemp Group, Inc. GBHPF (10)
  • Global Payout Inc. GOHE (109)
  • Global Realty Development Corp. GRLY (10)
  • Global Resource Corporation GBRC (48)
  • Global Roaming Distribution Inc. GRDB (34)
  • GlobalWise Investments Inc. GWIV (129)
  • GNCC Capital Inc. GNCP (24)
  • Golden West Brewing Company Inc. GWBC (3)
  • GoldSpring Inc. GSPG (4)
  • Google, Inc. GOOG (8)
  • (1)
  • Grandview Gold Inc. GVGDF (2)
  • Gray Publishing & Media, Inc. GPMIJ (15)
  • Graystone Park Enterprises Inc. GPKE (7)
  • Great Plains Holdings Inc. GTPH (28)
  • Green Earth Technologies GETG (1)
  • Green Star Alternative Energy Inc. GSAE (2)
  • Green Star Products Inc. GSPI (2)
  • Green Technology Solutions Inc. (GTSO) (19)
  • Greenbelt Resources Corp. GRCO (1)
  • Greenchek Technology Inc. GCHK (18)
  • Greenkraft, Inc. GKIT (22)
  • Greenstone Holdings Inc. GSHN (2)
  • Grey Cloak Tech, Inc. GRCK (24)
  • GRILLiT Inc. GRLT (8)
  • Growblox Sciences Inc. GBLX (24)
  • GT Legend Automotive Holdings Inc. GTLA (2)
  • GTX Corp GTXO (49)
  • Gulf Western Petroleum Corp. GWPC (3)
  • GWS Technologies Inc. GWSC (4)
  • Halcyon Jets Holdings Inc. HJHO (15)
  • Halitron Inc. HAON (11)
  • Hanover Financial Services (17)
  • Harbin Electric Inc. HRBN (2)
  • Harvey Electronics Inc. HRVE (1)
  • Hasco Medical Inc. HASC (7)
  • Hathway Corp. HWYI (1)
  • HeadsUp Entertainment International Inc. HDUP (3)
  • Healthnostics Inc. HNSO (1)
  • HealthSonix Inc. HSXI (1)
  • HealthSport Inc. HSPO (14)
  • Heartland Inc. HTLG (1)
  • Heartland Oil and Gas Corp. HTOG (7)
  • Hemis Corporation HMSO (19)
  • Hemisphere Gold Inc. HPGI (1)
  • Hemp Inc. HEMP (25)
  • Hendrx Corp. HDRX (1)
  • Hi-Shear Technology Corp. HSR (3)
  • HighCom Global Security Inc. HCGS (19)
  • HII Technologies Inc. HIIT (8)
  • Holloman Energy Corp. HENC (2)
  • Holmes Osborne (6)
  • Hologic Inc. HOLX (4)
  • Home Shopping Latino Inc. HSPG (8)
  • Hong Kong Highpower Technology Inc. HPJ (2)
  • HotOTC (61)
  • HotStockChat (3)
  • HotStockMarket (HSM) (3)
  • HST Global Inc. HSTC (11)
  • Hunt Gold Corp. HGLC (32)
  • HWI Global Inc. HWIC (3)
  • Hydrogen Corp. HYDG (1)
  • i-Level Media Group Inc. ILVL (3)
  • i2 Telecom International Inc. ITUI (7)
  • iB3 Networks Inc. IBNW (1)
  • IceWEB Inc. IWEB (5)
  • ICP Solar Technologies Inc. ICPR (3)
  • IDGLOBAL Corp. IDGJ (2)
  • IDO Security Inc. IDOI (22)
  • IEG Holdings Corp. IEGH (22)
  • IFAN Financial Inc. IFAN (34)
  • iGambit, Inc. IGMB (5)
  • Imaging3 Inc. IMGG (2)
  • ImaRx Therapeutics Inc. IMRX (2)
  • Immune Therapeutics Inc. IMUN (11)
  • Impact E-Solutions Corp. IESO (1)
  • Imperial Petroleum Inc. IPMN (10)
  • Inca Designs Inc. IDGI.PK (4)
  • Independent Film Development Corp. IFLM (1)
  • Index Oil and Gas Inc. IXOG.OB (5)
  • India Globalization Capital, Inc. IGC (21)
  • Industrial Biotechnology Corp. IBOT (1)
  • Infinite Group Inc. IMCI (48)
  • Inform Worldwide Holdings, Inc. IWWI (27)
  • InMed Pharmaceuticals, Inc. IMLFF (38)
  • Intec LTD ICLJY (1)
  • IntegraMed America Inc INMD (1)
  • Intelecom Inc. IECM (3)
  • Intelimax Media Inc. IXMD (31)
  • Intelligent Highway Solutions Inc. IHSI (6)
  • Intercept Energy Services Inc. IESCF (7)
  • Interleukin Genetics Inc. ILI (1)
  • International Barrier Technology Inc IBTGF (1)
  • International Consolidated Companies Inc. INCC (2)
  • International Stem Cell Corp. ISCO (226)
  • Inventergy Global Inc. INVT (15)
  • Investor Village (9)
  • Investors Business Daily (4)
  • InvestorsProfs (1)
  • InvestSource (11)
  • IPOs (8)
  • IR Biosciences Holdings Inc IRBS (3)
  • Isonics Corp. ISON (1)
  • ItsAboutFinance (2)
  • JC Data Solutions Inc. JCDS (4)
  • Joytoto USA Inc. JYTO (14)
  • JZZ Technologies Inc. JZZI (3)
  • KAL Energy Inc. KALG (3)
  • Kallo Inc. KALO (43)
  • Kandi Technologies Corp. KNDI (3)
  • KCM Holding Corp. KCMH (3)
  • Kingslake Energy Inc. KGLJ (2)
  • Klondex Mines Ltd. KLNDF (1)
  • Knobias KNBS (5)
  • Kootenay Zinc Corp. KTNNF (12)
  • Kraig Biocraft Laboratories Inc. KBLB (88)
  • L&L International Holdings Inc. LLFH (2)
  • Laguna Blends Inc. LAGBF (53)
  • Lantis Laser Inc. LLSR (5)
  • Last Mile Logistics Group LMLG (4)
  • Latitude 360 Inc. LATX (21)
  • LD Holdings Inc. LDHL (14)
  • Legacy Holdings Inc. LGYH (1)
  • Legacy Ventures International Inc. LGYV (24)
  • Legend Media Inc. LEGE (4)
  • Lexaria Bioscience Corp. LXRP (74)
  • Liberty Leaf Holdings Ltd. LIBFF (10)
  • Lifespan Inc. LSPN (1)
  • Lime Energy Corp. LIME (3)
  • Lingo Media Corp. LMDCF (18)
  • Linkwell Corporation LWLL (4)
  • Liquor Group Wholesale Inc. LIQR (22)
  • Inc. LFLS (47)
  • LOGIC Devices Inc. LOGC (1)
  • Logility Inc. LGTY (1)
  • LoJack Corp LOJN (3)
  • Longhai Steel Inc. LGHS (10)
  • LottoGopher Holdings Inc. LTTGF (26)
  • Lotus Pharmaceuticals Inc. LTUS (1)
  • Low Carbon Technologies (LWCTF) (3)
  • Lucas Energy, Inc. LEI (17)
  • Mabwe Minerals Inc. MBMI (56)
  • Macquarie Infrastructure Company MIC (5)
  • Maine and Maritime Corp. MMA (1)
  • Majic Wheels Corp. MJWL (6)
  • Makeup Inc. MAKU (2)
  • Mammoth Energy Group Inc. MMTE (5)
  • Mantra Venture Group Ltd. MVTG (10)
  • Marijuana Company of America, Inc. MCOA (37)
  • Mariner’s Choice International Inc. MCII (2)
  • Martin Nutraceuticals MNIU (11)
  • Material Technologies Inc. MTCH (44)
  • Max Media Group Inc. MXMI (9)
  • Max Sound Corp. MAXD (30)
  • MC Endeavors Inc. MSMY (2)
  • MedeFile International Inc. MDFI (46)
  • MediaG3 Inc. MDGC (1)
  • Medical Cannabis Payment Solutions (REFG) (13)
  • Medical Cannabis Payment Solutions REFG (19)
  • Medical Innovation Holdings, Inc. MIHI (16)
  • Medical Transcription Billing Corp. MTBC (13)
  • Medina International Holdings Inc. MIHI (3)
  • Medisafe 1 Technologies Corp. MFTH (3)
  • Medivisor Inc. MVSR (1)
  • Mega Media Group, Inc. MMDA (30)
  • MegaWest Energy Corporation MGWSF (2)
  • Memry Corp. MRY (2)
  • Metro One Development Inc. MODI (2)
  • Mexico Energy Corp. MXC (1)
  • MGX Minerals, Inc. MGXMF (52)
  • Micro Identification Technologies Inc. MMTC (44)
  • MicrocapMoney (2)
  • Microsoft Corporation MSFT (4)
  • Midway Gold Corp. MDW (1)
  • Military Resale Group MYRL (19)
  • Minco Silver Corp. MSV.TO (1)
  • Mindpix Corp. MNDP (1)
  • MIP Solutions Inc. MSOL (7)
  • MIT Holding MITD (36)
  • MitoPharm Corp. MTPH (1)
  • Mizati Luxury Alloy Wheels, Inc. MZTI (14)
  • Mobile Entertainment Inc. MBEI (1)
  • Mobile Lads Corp. MOBO (43)
  • Momentous Entertainment Group Inc. MMEG (19)
  • Monaker Group Inc. MKGI (48)
  • Money4Gold Holdings Inc. MFGD (3)
  • Holdings Inc. MBKR (2)
  • Mosquito Consolidated Gold Mines Limited MSQ.V (1)
  • Moxian Inc. MOXC (62)
  • mPhase Technologies Inc. XDSL (12)
  • MSE Enviro-Tech Corp. MEVT (4)
  • Muscle Flex Inc. MFLI (55)
  • MusclePharm Corp. MSLP (23)
  • Mvive Inc. MVIV (22)
  • My Automated Advisor (4)
  • MyECheck Inc. MYEC (99)
  • Inc. MYST (1)
  • Nanogen Inc. NGEN (2)
  • Nanometrics Inc. NANO (1)
  • NanoSensors Inc. NNSR (1)
  • NanoTech Entertainment Inc. NTEK (30)
  • Napster, Inc. NAPS (5)
  • National Automation Services Inc. NASV (67)
  • National Coal Corp. NCOC (2)
  • National Waste Management Holdings Inc. NWMH (24)
  • Naturally Iowa Inc. NLIA (2)
  • NavStar Technologies Inc. NVSR (16)
  • nCoat Inc NCOA (8)
  • Neah Power Systems NPWZ (14)
  • Neohydro Technologies Corp. NHYT (4)
  • Neoprobe Corp. NEOP (6)
  • NeoStem Inc. NBS (6)
  • Net Element Inc. NETE (19)
  • NetSol Technologies Inc NTWK (64)
  • Neurobiological Technologies Inc. NTII (3)
  • NeuroMama Ltd. NERO (15)
  • Neutra Corp. NTRR (37)
  • New Asia Gold Corp. NWAG (1)
  • New Generation Biofuel Holdings Inc. GNB (3)
  • NewMarket China Inc. NMCH (7)
  • NewMarket Technology Inc. NMKT (7)
  • Newport Digital Technologies Inc. NPDT (61)
  • Nexia Holdings Inc. NXHD (51)
  • NexMed Inc. NEXM (8)
  • NeXplore Corp. NXPC (4)
  • Next One Interactive Inc. NXOI (7)
  • NextGen Bioscience Inc. NXGB (1)
  • NextPhase Wireless Inc. NPHS (1)
  • Nexus Enterprise Solutions Inc. NXES (30)
  • NF Energy Saving Corp. of America NFES (1)
  • Nhale Inc. NHLE (18)
  • Nilam Resources Inc. NILR (4)
  • Nitro Petroleum Inc. NTRO (5)
  • North Bay Resources Inc. NBRI (10)
  • NuTech Inc. NTCI (1)
  • Nutra Pharma Corp. NPHC (21)
  • NutraNomics Inc. NNRX (30)
  • NuVim Inc. NUVM (1)
  • NVIDIA Corp. NVDA (1)
  • NXGen Holdings Inc. NXGH (1)
  • Oakridge Global Energy Solutions Inc. OGES (63)
  • Obee's Franchise Systems Inc. OBFM (1)
  • OBJ Enterprises Inc. OBJE (27)
  • Odyne Corporation ODYC (15)
  • Omega Commercial Finance Corp. OCFN (2)
  • OmniaLuo Inc. OLUO (1)
  • Omnicity Corp. OMCY (26)
  • Omninet Media.Com, Inc. ONMC (5)
  • On The Go Healthcare Inc. MODI (13)
  • On the Move Systems Inc. OMVS (102)
  • Oncolin Therapeutics Inc. OCOL (1)
  • One Step Vending Corp. KOSK (2)
  • One World Holdings Inc. OWOO (61)
  • Ones to Watch (1,353)
  • Onstream Media Corp. ONSM (5)
  • Onteco Corp. ONTC (4)
  • Open Energy Corp. OEGY (4)
  • Optical Systems Inc. OPSY (2)
  • Oramed Pharmaceuticals Inc. ORMP (2)
  • Organic Alliance Inc. ORGC (2)
  • ORHub, Inc. ORHB (32)
  • (82)
  • OtcStockExchange (5)
  • OurPet's Company OPCO (78)
  • OxySure Systems Inc. OXYS (23)
  • P2 Solar Inc. PTOS (24)
  • Pacific Gold Corp. PCFG (3)
  • Pamplona Picks (1)
  • Pan Global Corp. PGLO (82)
  • PanGenex Corp. PGCX (3)
  • Paramount Gold and Silver Corp. PZG (3)
  • Patient Access Solutions Inc. PASO (7)
  • Patriot Energy Corp. dba TelTeck Solutions Inc PGYC.PK (11)
  • Patriot One Technologies, Inc. PTOTF (25)
  • Patriot Scientific Corp. PTSC (6)
  • Peace Arch Entertainment Group Inc. PAE (1)
  • Peoples Educational Holdings Inc. PEDH (2)
  • Perf Go Green Holdings Inc. PGOG (12)
  • Perfect Web Technologies, Inc PWBI (11)
  • Perfectenergy International Ltd. PFGY (1)
  • Performance Health Technologies Inc. PFMH (31)
  • Pet DRX Corp. VETS (1)
  • Petro Resources Corp. PRC (2)
  • Petrogress, Inc. PGAS (27)
  • PetroSun Inc. PSUD (41)
  • Petroteq Energy Inc. PQEFF (50)
  • Phantom Fiber Corp. PHFB (2)
  • Pilot Financial Communications (3)
  • Pipex Pharmaceuticals Inc. PP (2)
  • PITOOEY! Inc. PTOO (14)
  • Pivot Pharmaceuticals Inc. PVOTF (1)
  • Planet Nutrition Inc. PNHL (4)
  • Platina Energy Group Inc. PLTG (8)
  • PlayBOX Inc. PYBX (5)
  • Players Network PNTV (15)
  • Pluristem Therapeutics Inc. PSTI (10)
  • Positron Corp. POSC (3)
  • PotNetwork Holding, Inc. POTN (59)
  • Power of the Dream Ventures (1)
  • Power Play Development Corp. PWPY (17)
  • Powersafe Technology Corp. PWSF (1)
  • Premier Energy Corp. PNRC (1)
  • Pressure BioSciences Inc. PBIO (41)
  • PreveCeutical Medical Inc. PRVCF (22)
  • PRG Group Inc. PRGJ (2)
  • PrimEdge Inc. PEDI (1)
  • Private Equity Securities (93)
  • Pro Motors Group Corp. PMGU (2)
  • Pro Travel Network Inc. PTVL (2)
  • ProBility Media Corp. PBYA (33)
  • ProGaming Platforms Corp. PPTF (22)
  • Proginet Corp. PRGF (3)
  • Prom Resources PRMO (9)
  • Propalms Inc. PRPM (3)
  • Provectus Pharmaceuticals Inc. PVCT (12)
  • Puget Technologies Inc. PUGE (23)
  • Pulmo BioTech Inc. PLMO (4)
  • Puramed Bioscience Inc. PMBS (3)
  • Pure Biofuels Corp. PBOF (4)
  • Pure H2O Inc. PURH (1)
  • Pure Hospitality Solutions Inc. PNOW (99)
  • Purio Inc. PURO (5)
  • Puritan Financial Group Inc. PTNG (1)
  • Purple Beverage Company Inc. PPBV (8)
  • QED Connect Inc. QEDC (4)
  • Qiao Xing Universal Telephone Inc. XING (2)
  • QPC Lasers Inc. QPCI (3)
  • Qualcomm Inc. QCOM (2)
  • QualityStocks for Women (16)
  • QualityStocks Partner StockGuru (3,878)
  • QualityStocks Stock Newsletter (551)
  • QualityStocks Stock Newsletters (18,172)
  • QualityStocks Video Charts (286)
  • Market Basics (6)
  • QualityStocksNewsBreaks (839)
  • Quantum Fuel Systems Technologies Worldwide Inc. QTWW (15)
  • Quantum International Corp. QUAN (3)
  • Quasar Aerospace Industries Inc. QASP (6)
  • QuoteMedia Inc. QMCI (120)
  • Rafarma Pharmaceuticals Inc. RAFA (31)
  • Rainbow Coral Corp. RBCC (33)
  • Rancher Energy Corp. RNCH (9)
  • Raptor Resources Holdings Inc. RRHI (50)
  • Raven Gold Corp. RVNG (3)
  • Red Lake Exploration Inc. RLKX (19)
  • RegalWorks Media Inc. RWMI (4)
  • Regenicin, Inc. RGIN (6)
  • Reign Sapphire Corp. RGNP (13)
  • Reliant Financial Services Inc. RFNS (1)
  • Renhuang Pharmaceuticals Inc. RHGP (3)
  • ReoStar Energy Corp. REOS (1)
  • Resort Savers Inc. (RSSV) (10)
  • Revett Minerals (1)
  • RJD Green Inc. RJDG (19)
  • Rock Energy Resources Inc. RCKE (4)
  • Rodman & Renshaw (432)
  • Ronn Motor Company Inc. RNNM (6)
  • Rox Resources Ltd. RXRS (3)
  • Royal Quantum Group, Inc. RYQG (10)
  • Royal Standard Minerals Inc. RYSMF (2)
  • Rudy Nutrition RUNU (27)
  • RXi Pharmaceuticals Corp. RXII (3)
  • Santa Fe Gold Corp. SFEG (5)
  • Santa Fe Holding Company SFHD (3)
  • Save The World Air Inc. ZERO (12)
  • Savoy Energy Corp. SNVP (26)
  • SavWatt USA, Inc. SAVW (5)
  • Seabridge Gold Inc. SA (1)
  • Seawright Holdings Inc. SWRI (1)
  • Sector 10 Inc. SECI (78)
  • SES Solar Inc. SESI (2)
  • Seven Arts Pictures plc SAPX (1)
  • Seven Arts Pictures PLC SAPXF (5)
  • Shazam Stocks (22)
  • ShotPak Inc. SHTP (35)
  • Shumate Industries SHMTE (1)
  • Sibling Group Holdings Inc. SIBE (55)
  • Sierra Gold Corp. SGCP (2)
  • Signature Devices Inc. SDVI (9)
  • Silver Dragon Resources Inc. SDRG (1)
  • Silver Falcon Mining Inc. SFMI (1)
  • SilverSun Technologies Inc. SSNT (30)
  • Simtrol Inc. SMRL (74)
  • Simulated Environment Concepts Inc. SMEV (130)
  • Singlepoint Inc. SING (150)
  • Sino Agro Food Inc. SIAF (1)
  • Sinobiomed Inc. SOBM (4)
  • Sinovac Biotech Ltd SVC (1)
  • Sipp Industries Inc. SIPC (2)
  • Sixty Six Oilfield Services Inc. SSOF (1)
  • Skinny Nutritional Corp. SKNY (19)
  • Skinvisible, Inc. SKVI (41)
  • Sky Petroleum Inc. SKPI (1)
  • SkyPostal Networks Inc. SKPN (66)
  • Small Cap Sentinel (2)
  • Small Cap Sleeper (3)
  • Smallcap Bullets (2)
  • (22)
  • SmallCapVoice (428)
  • Smoky Market Foods Inc. SMKY (9)
  • SocialPicks (1)
  • Sofame Technologies Inc SDW.V (1)
  • Sohm Inc. SHMN (14)
  • Solanex Management Inc. SLNX (15)
  • Solar Energy Initiatives Inc. SNRY (14)
  • Solar Wind Energy Tower Inc. SWET (15)
  • Solarfun Power Holdings Co. Ltd. SOLF (2)
  • Soul and Vibe Interactive Inc. SOUL (14)
  • South Sea Energy Corp. SSGY (7)
  • Soyo Group Inc SOYO (2)
  • SpaceDev Inc. SPDV (5)
  • Sparta Commercial Services Inc. SRCO (31)
  • Speedemissions Inc. SPMI (14)
  • Spicy Pickle Inc SPKL (18)
  • SpongeTech Delivery Systems Inc. SPNG (14)
  • Sports Pouch Beverage Company Inc. SPBV (1)
  • Star Mountain Resources Inc. SMRS (37)
  • Start Scientific Inc. STSC (22)
  • Stealth Technologies, Inc. STTH (3)
  • Stock Market E-News (1)
  • Stock Promoters (4)
  • StockEgg (14)
  • Stocks to Watch (1,951)
  • StocksJournal (2)
  • StockUPTicks (165)
  • Stockwire (6)
  • Strategic American Oil Corp SGCA (32)
  • Stratos Renewables Corp. SRNW (89)
  • StreamTrack Inc. STTK (31)
  • Striker Oil & Gas Inc. SOIS (4)
  • Sun Motor International Inc. SNMO (1)
  • SUN Sports & Entertainment Inc. SSPE (3)
  • Sunshine Biopharma Inc. SBFM (6)
  • Superlattice Power Inc. SLAT (60)
  • SupportSave Solutions, Inc. SSVE (10)
  • Surefect Holdings Inc. SUFH (1)
  • Suspect Detection Systems Inc. SDSS (37)
  • Sweet Success Enterprises Inc. SWTS (35)
  • Swiss Hawk AG SWHKF (1)
  • Symposium Production Corp. SYPJ (1)
  • Tactical Air Defense Services, Inc. TADF (15)
  • Tao Minerals Ltd. TAOL (1)
  • TapImmune, Inc. TPIV (15)
  • Tapinator, Inc. TAPM (26)
  • Taplmmune Inc. TPIM (1)
  • Technology Applications International Inc. NUUU (25)
  • TechPrecision Corp. TPCS (4)
  • Tecton Corp. TTNC (3)
  • Teewinot Life Sciences (9)
  • Teknik Digital Arts Inc. TKNK (10)
  • Telanetix Inc. TNXI (2)
  • Teletouch Communications Inc. TLLE (5)
  • Terax Energy Inc. TEXG (32)
  • Terme Bancorp TMEB (1)
  • Terra Nostra Resources Corp. TNRO (25)
  • The Amergence Group AMNG (8)
  • The Aristocrat Group Corp. ASCC (113)
  • The Bowser Report (68)
  • The Bull Report (32)
  • The Capital Report (5)
  • The DIRECTV Group Inc. DTV (1)
  • The Fight Zone Inc. TFZI (12)
  • The Green Organic Dutchman Holdings Ltd. TGOD (11)
  • The Guitammer Company Inc. GTMM (38)
  • The International Traders Expo (30)
  • The Mobile Star Corp. MBST (7)
  • The Motley Fool (3)
  • The Mundus Group Inc. MNDS (1)
  • The Penny Stock Blog (28)
  • The Principal Structure Fund, Inc. PSF (2)
  • The Tracking Corp. TRKG (1)
  • The UpTurn, Inc. UPTR (20)
  • The Wall Street Savant (24)
  • The Wide Angle (3)
  • Thresher Industries Inc. THRR (15)
  • Tidelands Oil and Gas Corp. TIDE (1)
  • Tiens Biotech Group USA Inc. TBV (1)
  • TMT Capital Corp. TMTP (1)
  • TNI BioTech Inc. TNIB (16)
  • Tombstone Exploration Corp. TMBXF (9)
  • TOMI Environmental Solutions Inc. TOMZ (4)
  • Tootie Pie Company, Inc. TOOT (11)
  • Torchlight Energy Resources, Inc. TRCH (2)
  • TradeShow Marketing Company Inc. TSHO (21)
  • TransWorldNews (4)
  • Tri-Star Holdings Inc. TSHL (31)
  • Trimax Corp. TMXN (31)
  • TripleCrownStocks (9)
  • True 2 Beauty Inc. TRTB (43)
  • TwinTrader (8)
  • TXP Corporation TXPO (1)
  • TZ Ltd. TZL.AX (1)
  • U.S. Mine Makers Inc. USMM (1)
  • uKarma Corporation UKMA (1)
  • Ultitek Ltd. UITK (21)
  • Unbridled Energy Corporation TSX-UNE (21)
  • Unico Inc. UNCO (3)
  • Universal Bioenergy Inc. UBRG (3)
  • Universal Detection Technology UNDT (41)
  • Universal Energy Corp. UVSE (19)
  • Universal Property Development and Acquisition UPDA (4)
  • Universal Tracking Solutions Inc. UTRK (13)
  • Universal Travel Group UTVG (14)
  • UpSNAP Inc. UPSN (1)
  • Uranium Energy Corp. UEC (64)
  • Uranium Hunter Corp. URHN (17)
  • Urex Energy Corp. URXE (1)
  • USA Recycling Industries Inc. USRI (21)
  • USA Superior Energy Inc. USSU (9)
  • Ustelematics Inc. UTLM (27)
  • Utah Uranium Corp. UTUC (2)
  • Utilicraft Aerospace Industries Inc. UITA (2)
  • ValueRich & iValueRich (9)
  • Vaporin Inc. VAPOD (2)
  • VentriPoint Diagnostics Ltd. VPTDF (26)
  • Veritas Pharma Inc. VRTHF (17)
  • Vermillion Inc. VRML (3)
  • Vertical Branding Inc. VBDG (11)
  • VIASPACE, Inc. VSPC (185)
  • Victory Energy Corp. VYEY (29)
  • Victory Square Technologies Inc. VSQTF (2)
  • Vidshadow Inc. VSHD (1)
  • View Systems Inc. VSYM (16)
  • Viper Networks Inc. VPER (2)
  • Viral Genetics Inc. VRAL (3)
  • Viropro International Inc. VPRO (2)
  • VirTra Systems Inc. VTSI (22)
  • Viscount Systems Inc. VSYS (27)
  • visionGATEWAY Inc. VGWA (1)
  • VistaGen Therapeutics Inc. VSTA (104)
  • Visualant Inc. VSUL (5)
  • Vital Products Inc. VTLP (5)
  • Viyya Technologies Inc. VYON (2)
  • VizStar Inc VIZS (24)
  • Voiceserve Inc. VSRV (18)
  • Vortex Resources Corp. VTEX (7)
  • Vsurance Inc. VSUR (3)
  • Vyteris Inc. VYHN (1)
  • W2 Energy Inc. WWEN (13)
  • Wall Street News Alert (76)
  • WallStreetGrapevine (12)
  • WaterPure International Inc. WPUR (4)
  • Wave Systems Corp. WAVX (5)
  • Week in Review (2)
  • Well Power Inc. WPWR (77)
  • Wescorp Energy Inc. WSCE (18)
  • West Canyon Energy Corp. WCYO (1)
  • Western Standard Energy Corp. WSEG (7)
  • Who's Your Daddy Inc. WYDI (7)
  • WikiLoan Inc. WKLI (14)
  • Wind Energy America Inc. WNEA (3)
  • Wisdom Homes of America Inc. WOFA (15)
  • Wits Basin Precious Minerals Inc. WITM (2)
  • Woize International Ltd. WOIZ (1)
  • WordLogic Corp. WLGC (40)
  • Workstream Inc. WSTM (9)
  • WorldWater & Solar Technologies Corp. WWAT (10)
  • Worldwide Energy and Manufacturing WEMU (12)
  • Worldwide Manufacturing USA Inc. WWMU (6)
  • WRIT Media Group Inc. WRIT (36)
  • X-Change Corp. (XCHC) (2)
  • Xaar Plc XAARF (1)
  • Xenomics Inc. XNOM (1)
  • XsunX Inc. XSNX (17)
  • XZERES Corp. XPWR (2)
  • Younger America YNGR (13)
  • Zacks Investment Research (11)
  • ZAGG Inc. ZAGG (9)
  • Zaldiva Inc. ZLDV (3)
  • ZAP ZAAP (15)
  • ZBB Energy Corp ZBB (7)
  • Zenosense Inc. ZENO (53)
  • Zentric Inc. ZNTR (14)
  • Zevotek Inc. ZVTK (8)
  • Zinc One Resources Inc. ZZZOF (7)
  • Znomics Inc. ZNOM (3)
  • Newsletter Signup

    Stay ahead of the pack with QualityStocks and receive "The QualityStocks Daily", our summary formatted newsletter containing stock tips from hundreds of online investment newsletters.

    Rotate your device 90° to view site.